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ABSTRACT 
 
RITA-MARIE THOMAS MCFADDEN:  The Role of Curcumin in Modulating Colonic 
Microbiota During Colitis and Colon Cancer Prevention 
(Under the direction of Pawel Kiela) 
 
 
 Background: Inflammatory bowel diseases (IBD) are a major risk factor for colon 
cancer.  Intestinal microbiota have been identified as the target of inflammation that affects the 
progression of colitis-associated colorectal cancer (CAC).  With diet being a key determinant of 
the gut microbial ecology, dietary interventions are an attractive avenue for the prevention of 
CAC. Curcumin is the most active constituent of the ground rhizome of the Curcuma Longa 
plant, which has been demonstrated to have anti-inflammatory, anti-oxidative, pro-apoptotic and 
anti-proliferative properties.  However, the exact role of curcumin in colon cancer prevention 
and modulation of the microbial communities are yet to be determined.  Methods: A mouse 
model of CAC was utilized in which Il10
-/-
 mice on 129/SvEv background develop progressive 
colitis.  On the starting day, WT or Il10
-/-
 mice received a 100µL i.p. injection of 10mg/kg body 
weight of azoxymethane (AOM) or sterile saline (continued once a week for six weeks total) and 
were started on one of the following curcumin-supplemented diets: 0%, 0.05%, 0.1% or 0.5%. 
Mice were monitored for weight loss, rectal prolapse, rectal bleeding, and stool consistency.  
Stools were collected every four weeks for microbial analysis (Illumina 16S rRNA profiling). At 
the conclusion of the study, mice were assessed for tumor burden, colonic histopathology and 
colonic cytokine profile. Results: Curcumin-supplemented diets increased survival, decreased 
colon weight/length ratios and reduced tumor burden in a dose-dependent manner.  Distal colon 
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histopathology in Il10
-/- 
mice exposed to AOM with the 0.5% curcumin diet demonstrated a 
reduction of inflammation score and a reduction in the frequency of adenocarcinoma detection.  
Curcumin altered the microbial ecology in the gut of Il10
-/- 
mice fed the 0.5% curcumin diet.  
DIfferences in microbial diversity were observed in mice with tumors vs. without, as well as in 
mice that had spontaneous vs. AOM-induced tumors. Conclusions: In a dose-dependent manner, 
dietary curcumin results in a less severe presentation of colitis, in a reduced risk of progression 
to CRC upon exposure to AOM and a more diverse colonic microbial ecology in the Il10
-/-
 mice.  
This suggests that curcumin functions as an effective agent for restoring healthy gut homeostasis.  
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CHAPTER 1:  INTRODUCTION 
 
1.  Significance 
Chemopreventive agents, which are utilized to prevent the onset of cancer, can have 
numerous side effects that prevent their efficacy and long-term administration to high risk 
patients.  However, plant-based dietary supplements circumvent this problem by providing 
effective and less toxic alternatives.  A promising chemopreventive agent is curcumin, a 
component of the cooking spice Turmeric, which derives from a rhizome of the Curcuma longa 
plant.  Curcumin has been demonstrated to function as an antiseptic, analgesic, anti-
inflammatory, antioxidant, antimalarial, and chemopreventive agent.  It is primarily administered 
orally as a dietary supplement, which would potentially have direct contact with the gut 
microbiota.  A gap in the field is the impact of curcumin on the microbiota of patients.  Dysbiosis 
of a patient’s gut microbiota is associated with chronic inflammatory bowel disease and an 
increased risk for colon cancer.  Understanding the exact mechanistic roles of curcumin is a 
rapidly expanding field due to the promise of this naturally-derived treatment for cancer patients.  
This laboratory has extensively studied the benefits of curcumin in reducing colonic 
inflammation through direct inhibition of neutrophil migration (Larmonier et al., 2011), through 
an IL-10-dependent mechanism (Larmonier et al., 2008), depending on the type of inflammation 
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(Th1 or mixed Th1/Th2), which varies by mouse strain (Billerey-Larmonier et al., 2008) and 
through inhibiting IFN-γ signaling in colonic epithelial cells (Midura-Kiela et al., 2011).  This 
laboratory has also demonstrated that curcumin can interact with PTPN1 tyrosine phosphatases 
to increase dephosphorylation of cortactin, which inhibits cortactin’s function in cancer cell 
motility and invasion (Radhakrishnan, et al., 2014).  
This thesis proposes that the role of curcumin is closely linked to the regulation of 
microbiota during the onset and persistence of inflammatory bowel diseases (IBD), such as 
ulcerative colitis, as well as the associated progression to cancer. Ulcerative colitis is 
characterized by severe colon inflammation and the formation of numerous polyps.  5-10% of 
patients who have been diagnosed with ulcerative colitis for 10 years progress to colon cancer, 
while the risk of developing colon cancer in patients diagnosed with ulcerative colitis for over 30 
years increases to 15-40%.  Colon cancer is the third most commonly diagnosed cancer in the 
United States of America (U.S.A.) with an estimated 136,830 new cases diagnosed in the year 
2014.  Colon cancer has one of the highest mortality rates of cancers in the U.S.A. at 9%, which 
is greater than that of pancreatic cancer and leukemia combined.  Colon cancer is the third 
leading cause of cancer related death in both men and women in the U.S.A (American Cancer 
Society, 2014).  Despite effective screening and diagnostics, incidence and mortality remains 
high, while the mechanisms underlying the link between colon inflammation and cancer 
progression remain poorly understood.   
Elucidating the effect of curcumin on gut microbiota would potentially provide a novel 
therapeutic for IBD, as well as for colon cancer.  Furthermore, the impact of this research may 
extend to other fields where diseases are characterized by an improper regulation of 
inflammation, such as autoimmune disorders.   
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2.  Inflammatory Bowel Disease and Colon Cancer 
It is estimated that 1 million people in the United States of America (U.S.A.) have 
inflammatory bowel disease, split evenly between Crohn’s Disease and Ulcerative Colitis 
(Crohn’s & Colitis Foundation of America, 2014).  Incidence of IBD is estimated to be 
396/100,000 people worldwide.  Age of onset is typically 15 – 30 years of age with 10% of cases 
in patients below 18 years of age.  Major risk factors include genetic predisposition (family 
history of IBD) and environmental factors, such as “Westernized” diets high in red meat, high in 
fat and low in fiber.  There is an increased incidence of colon cancer in patients with IBD, 
particularly with Ulcerative Colitis.  The incidence is higher for “Westernized” nations.  Within 
the United States alone, it is estimated that 1 in 19 people will develop colon cancer in their 
lifetime (American Cancer Society, 2014).  However, the link between inflammation and 
carcinogenesis in the colon remains unclear.   
 
2-1  Overview of inflammatory bowel diseases (IBD) 
2-1-a Crohn’s Disease (CD)  
Crohn’s disease is characterized by chronic inflammation that can affect any area of the 
gastrointestinal tract and any layer of the intestinal wall.  It can have “skip lesions” with areas of 
healthy mucosa in between.  Symptoms include diarrhea, cramping, fever, fatigue, rectal 
bleeding and blockage of the intestine resulting in vomiting, cramping and bloating.  Ulcerations 
can occur and develop fistulas, which can become infected in 30% of patients on average.  
Medicinal strategies include aminosalicylates, antibiotics, tumor necrosis factor blockers, such as 
Infliximab and drugs used as to aid in immunosuppression, such as Azathioprine, 
Mercaptopurine (6-MP) and Methotrexate.  Patients may undergo surgery to remove affected 
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areas in the colon.  The Center for Disease Control (CDC) estimates that the worldwide 
incidence of Crohn’s is 0.1-16/100,000 people.  This is a conservative estimate, due to lack of 
proper or inconsistent diagnoses.  CD trends towards a higher prevalence in women.  CD is more 
prevalent in smokers than non-smokers (CDC, 2014). 
 
2-1-b Ulcerative Colitis (UC) 
Ulcerative colitis is characterized by chronic inflammation that primarily affects the 
mucosa layer of the colon.  The distal most region of the colon is affected and the inflammation 
may progress proximally and continually.  Symptoms include bloody stool, cramping, bloating, 
weight loss, feeling the severe need to have a bowel movement, nausea and fever.  The 
symptoms can have periods of remission and flare-ups.  Patients can develop bleeding ulcers and 
ruptures within the colon.  Children with UC may experience stunted growth.  Medicinal 
strategies are the same as listed above for CD, although colectomy surgery will “cure” UC, as it 
only affects the colon tissue.  The CDC estimates that the worldwide incidence of UC is 0.5-
24.5/100,000 people.  Ulcerative Colitis has received much attention in colon cancer research 
due to the increased incidence of those patients to develop colon cancer, although patients with 
CD also develop colon cancer (CDC, 2014). 
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Figure 1.1: Comparison of Crohn’s Disease (CD) and Ulcerative Colitis UC) 
 
 
2-2  Overview of colon cancer 
The immune system is the body’s coordinated network of cells and proteins that help 
distinguish and eliminate mutated cells, as well as foreign materials, such as macromolecules, 
chemicals and microorganisms (Abbas et al., 2007).  If improperly regulated, the immune 
response will begin to harm and eliminate healthy cells.  Furthermore, many cancers, notably 
colon cancer, can arise during conditions of chronic inflammation.  Cancer is defined by the 
American Cancer Society as a group of diseases characterized by the uncontrolled growth and 
spread of abnormal cells (American Cancer Society, 2010).  Cancer is a broad term 
encompassing diseases that cross gender, ethnic, age and socioeconomic boundaries.  Cancer is 
the second leading cause of death in the United States of America preceded only by heart disease 
and it is characterized by the following hallmarks: 1) self-sufficiency in growth signals, 2) 
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evading apoptosis (programmed cell death), 3) sustained angiogenesis (formation of blood 
vessels), 4) Insensitivity to antigrowth signals, 5) limitless potential for replication, and 6) tissue 
invasion and metastasis (Hanahan and Weinberg, 2000).  Inflammation is characterized by an 
influx of phagocytic “innate” immune cells, followed by more specific “adaptive” immune cells 
that coordinate the response to infections, wounds and foreign antigens.  However, the cancer 
cells arise from host cells and a) may not be recognized as foreign and b) produce factors or gain 
mutations to facilitate evasion of the immune response and cell cycle control.  There is a delicate 
balance among the commensal microbial flora and the resident tissue cells that normally undergo 
a large amount of proliferation, as well as programmed cell death, termed apoptosis, as those 
resident tissue cells slough off to aid in proper bowel function.  Thus, the colon is an ideal 
location for development of cancer, since the healthy colon tissue is already rich in growth 
factors to support the high proliferation rate of gut epithelial cells.  Colon cancer is the third 
most commonly diagnosed and the third highest cause of cancer mortality in the U.S.A. It is 
estimated that 136,830 people will be diagnosed in the U.S.A. during 2014 and 50,310 will die 
from colon cancer in 2014 (American Cancer Society, 2014).  Incidence has decreased due to 
better screening for malignant growths via endoscopies and colonoscopies.  Colon cancer 
symptoms are fairly non-specific, including cramping in the abdomen, decreased appetite, 
unintentional weight loss, constipation or diarrhea that lasts for days, narrow stool, dark-colored 
stool and/or bleeding from the rectum.  There is a close association with a medical history of 
chronic inflammatory bowel disease and the progression to colon cancer.  A question arises 
concerning the transition from inflammation to colon cancer and the regulation of the immune 
system during this disease process.   
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Figures 1.2 and 1.3 summarize the immune responses, including sub-populations of T-
cells, such as Th1 and Th2 and their associated cytokines, which contribute to homeostasis or 
IBD.  The immune system within the intestine contributes to wound healing, protection from 
pathogens and physiologic immune tolerance of luminal antigens.  During IBD, aberrant mucosal 
infiltration within the lamina propria can occur by neutrophils, macrophages, dendritic cells, as 
well as T and B cells.  This process correlates with increased production of the pro-inflammatory 
cytokines TNFα, IL-1β, IFNγ, IL-6, IL-1β, IL-12/23 p40 and IL-17.   
 
2-3  Immune system responses contributing to colitis-associated colon cancer 
 
 
 
Figure 1.2: Immune system during colon homeostasis 
Modified from: Larmonier, C. 2010.  Novel therapeutic strategy for the treatment of Inflammatory Bowel Diseases.  Doctoral 
thesis. 
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Figure 1.3: Immune cell response during colitis 
Modified from: Larmonier, C. 2010.  Novel therapeutic strategy for the treatment of Inflammatory Bowel Diseases.  Doctoral 
thesis. 
 
 
2-3-a CD4
+
 Th cells 
The two types of IBD, Crohn’s Disease (CD) and Ulcerative Colits (UC) are classically 
thought to differ by CD4
+
 Th responses and cytokine production.  CD is characterized by a 
Th1/Th17 response with increased IL-2, IL-12 and IFN-γ cytokine production.  CD can occur 
anywhere along the gastrointestinal tract and contain skip lesions with areas of normal mucosa in 
between.  UC is characterized by a Th2 response with increased IL-4, IL-5 and IL-13 cytokine 
production.  UC tends to occur in the distal most region of the colon and progress proximally and 
is restricted to the mucosal layer.  Ifn-γ-/- mice deficient in IFN-γ production have increased 
production of IL-4 and IL-5 and are skewed towards a Th2 response.  These mice have increased 
tumor burden, which correlates with the clinical observation that human patients with UC are 
more likely to progress to colon cancer than patients with CD, indicating a possible connection 
between Th1 responses and better prognoses.  However, other factors may be biasing the results, 
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such as the role of IFN-γ to activate cells with anti-tumor functions, such as cytotoxic CD8+ T 
cells and NK cells.  Experiments that were conducted to skew Th1 responses to Th2 responses 
used neutralization antibodies to p40, a subunit of IL-12.  However, this subunit is shared by IL-
23, which is critical to maintenance of Th-17 cells.  Mice deficient in the transcription factor for 
Th-17 cells, RORγt, are resistant to inflammation.  The IL-17 cytokine produced by Th-17 cells 
promote the expression of TNF-α, IL-6, IL-1, iNOS and various metalloproteinases and 
chemokines that are associated with the onset of colitis-associated colon cancer (Rizzo et al., 
2011).  This indicates that there are differences in severity and progression of colitis based on the 
CD4
+
 Th subtype.  For these reasons, mRNA expression of IL-17, IL-6, TNF-α, IL-1, IFN-γ, IL-
12 and IL-23 within colon tissue was tested. 
 
2-3-b. IL-6 
Interleukin-6 (IL-6) is of particular interest as it is a pro-inflammatory cytokine that has 
been demonstrated to have increased expression in patients with active UC and those who have 
progressed to CAC, compared to individuals in a control group.  Furthermore, IL-6 expression 
contributes to resistance to apoptosis in T cells, as well as in normal and transformed colonic 
epithelial cells (STAT-3-dependent mechanism).  A study disrupted the suppressor of cytokine 
signaling 3 (SOCS3), which would normally limit the IL-6 activation of STAT-3.  As a result, 
the colonic tumor burden and average size increased (Rigby et al., 2007).  The inhibition IL-
6/STAT3 mechanism was shown to underlie the anti-cancer effect of a small molecule inhibitor, 
Embelin against colitis-associated colon cancer (Dai et al., 2014).  IL-6 can inhibit TGF-ß 
signaling via induction of Smad7, contributing to an uncontrolled immune response.  Mice 
deficient in Smad3, a regulator of TGF-ß signaling, develop CAC.  Transforming growth factor 
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(TGF)-ß plays a regulatory role to suppress the immune system.  Deficiency of the receptor 
TGF-ßRII in dendritic cells is sufficient to cause autoimmunity in multiple organs (Ramalingam 
et al, 2012).  The numerous direct and downstream effects of IL-6 indicate that it has a pivotal 
role in CAC. 
 
2-3-c. TNF-α 
TNF-α is of special interest in the field of digestive diseases.  Anti-TNF-α is a therapy 
currently utilized in the clinic for CD and UC patients.  A retrospective study addressed the 
efficacy of the anti-TNF- α treatments infliximab and adalimumab in 33 pediatric patients and 
showed that mucosal healing occurred in over 44% of the patients and that the overall clinical 
response was improved to greater than 80% for both medications (Nobile et al., 2014).  TNF- α 
is critical to the progression of chronic inflammation and CAC due to its role in activation of NF-
κ α B, a transcription factor for pro-inflammatory cytokines and factors that increase cell 
proliferation, angiogenesis, apoptosis-evasion and metastasis.  When NF-κB activation is 
blocked through deletion of IKKβ in the intestinal epithelium, epithelial cell apoptosis increases 
during early tumor development and the incidence of CAC decreases (Greten et al., 2004).  
Furthermore, chronic, elevated production of TNF- α is associated with elevated tumor burden in 
experimental models.  Mice deficient for the p55 subunit for the receptor of TNF- α did not 
develop tumors (Popivanova et al., 2008).  Tumor burden and size decreased in mice treated with 
MP6-XT22, a neutralizing monoclonal antibody to TNF- α, during an AOM/DSS colitis-
associated cancer induction model (Onizawa et al., 2009).  This indicates the crucial role of 
TNF- α in CAC. 
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2-3-d. IL-10 
A cytokine that functions to suppress the immune system is Interleukin-10 (IL-10).  Mice 
deficient in IL-10 spontaneously develop colitis and treatment with exogenous IL-10 restores a 
healthy phenotype.  IL-10 has been shown to have antiangiogenic properties, as well as 
inhibitory properties for NF-κB activation.  A study testing 282 patients for two candidate 
cancer-associated SNPs in IL-10 as potential prognostic biomarkers demonstrated that patients 
with the IL-10 rs3021094 polymorphism had a 3.3 fold higher risk of death (Ting et al., 2013).  
Treg transfer from IL-10-deficient mice failed to reduce tumor burden in colon cancer-prone 
Apc
Min
 mice, while Treg transfer from healthy wildtype mice did reduce tumor burden through 
induction of epithelial cell apoptosis and downregulation of Cox-2 in dysplastic epithelium 
(Erdman et al., 2005).  This indicates that IL-10 plays a critical role in CAC.  Thus, an 
established model of CAC using IL-10
-/-
 mice that develop spontaneous, progressive colitis 
(Wirtz et al, 2007) was chosen to address this study. 
  
2-3-e. CD8
+
 Th cells 
Other adaptive immune cells also contribute to disease progression in the colon.  CD8
+
 
Th cells can directly act on tumor cells by a) permeabilization mediated by their production of 
perforin, granzyme A and granzyme B, b) expression of FasL, which interacts with Fas on 
dysplastic cells to induce programmed cell death, apoptosis and c) production of IFN-γ, which 
can upregulate Fas on tumor cells (Rizzo et al., 2011).  In fact, colon cancer cells have an 
immune system escape mechanism that facilitates the killing of CD8
+
 T cells through expression 
of CCL5 and Treg infiltration to the tumor site (Chang et al., 2012).   
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2-3-f. NKT cells 
NKT cells can express both Th1 and Th2 cytokines.  Activation of NKT cells with alpha-
galactosylceramide was sufficient to protect mice from DSS-induced colitis, indicating a 
protective role in IBD (Saubermann et al., 2000).  NKT cells may be tumor enhancers or 
suppressors, depending on the context.  Type I NKTs that express V- α -14-J α -18 TCR- α 
chain are protective in the gut by promoting IFN-γ expression, CD8+ cell activation and NK cell 
activation (Kitamura et al., 1999; Yang et al., 2000).  Type I NKT cell infiltration into tumors is 
associated with better prognosis for human patients.  However, type II NKT cells that do not 
express the V-a-14-Ja-18 TCR- α chain function to suppress the immune system and, thus, 
enhance tumor growth (Rizzo et al., 2011).   
 
2-3-g. NK cells 
Innate immune cells also play a role in inflammation and cancer progression in the colon.  
Natural Killer (NK) cells have been demonstrated to have a protective effect in DSS-induced 
colitis, as indicated by increased colonic damage, increased leukocyte infiltration and increased 
production of pro-inflammatory cytokine production following NK depletion by a polyclonal 
anti-asialo GM1 antibody, as well as NK cell deficient mice (Hall et al., 2013).  Activated NK 
cells express IFN-γ, perforin and granzymes that function to induce apoptosis in tumor cells.  
CRC patients that contain MICA-expressing tumor cells have a better prognosis.  MICA is a 
NKG2D ligand, which functions to activate NK cells (Terabe et al., 2000).  Patients with colon 
cancer were shown to have reduced expression of NKG2D and another NK cell activating 
ligand, DNAM-1.  Inhibition of NKG2D and DNAM-1 resulted in reduced cytotoxicity functions 
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of NK cells against tumor cells (Zhang et al., 2012).  This demonstrates the anti-cancer role of 
NK cells in colon cancer.   
 
 
2-3-h.  M1 and M2 macrophages 
Macrophages are tissue-specific mononuclear cells of the innate immune system that are 
able to uptake non-specific antigens or dying cells through phagocytosis.  Activated 
macrophages have increased expression of MHCII molecules and the co-stimulatory B7 
molecule, which function to activate T helper cells.  Macrophage activation has been further 
described as either classical (M1) or alternative (M2).  M1 macrophages are generally 
characterized as promoting inflammation, while M2 macrophages are characterized as 
suppressing inflammation.  IFN-γ, along with Lipopolysaccharide (LPS) is the primary 
stimulatory factors for M1 activation.  M2 have various stimuli, which can include IL-4, IL-13, 
glucocorticoids and IL-10 (Martinez et al., 2014).   
Polarizing macrophages from an M1 phenotype to an M2 phenotype has been explored to 
reduce colitis.  Lactobacillus plantarum CLP-0611 has been used as a probiotic in experimental 
mice to not only reduce IL-1beta expression, IL-6 expression and NF- B activation, but to also 
significantly reduce the severe effects of the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced 
colitis in experimental mice through an M1 shift to M2 macrophage activation mechanism (Jang 
et al., 2014).  Likewise, commensal bacteria can potentially cause a shift to M1 macrophages and 
trigger colitis, as is the case for Enterococcus faecalis (Yang et al., 2013).   
In human monocyte-derived macrophages, Wnt signaling pathways have been 
demonstrated to be activated by M2 polarized cells, but not M1, and were associated with a 
reduction of the alkaline phosphatase activity and decreased enterocyte differentiation in 
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epithelial cells.  These results corresponded to analysis of the mucosa in UC patients where M2 
macrophages increase in abundance the longer a patient has been diagnosed with the disease and 
is correlated with activation of epithelial Wnt signaling and reduced enterocyte differentiation, 
implicating a possible mechanism of these cell types in IBD progression (Cosín-Roger et al., 
2013). 
However, the lineages of macrophage phenotypes may serve different roles, depending 
on the disease context.  Conditioned media collected from differentiating macrophages to the M1 
phenotype (by exposure of IFN-γ and LPS), was sufficient to induce cell cycle arrest and 
apoptosis in 20% of the HT-29 colon cancer cell line culture, which indicates that macrophages 
may have a beneficial anti-cancer role, independent of inflammation (Engström et al., 2014).  
Understanding how gut microbiota can affect activation of immune cells may be critical to 
understanding the switch from inflammation to colon cancer, as well as in design of therapeutics 
utilizing gut microbiota.   
 
3.  Colon cancer etiology in humans 
Benign adenomatous polyps precede many malignant colorectal cancers, although there 
are colon cancers associated with specific familial syndromes, such as familial adenomatous 
polyposis (FAP).  FAP is well described as being characterized by hundreds of polyps along the 
colon tissue and as deriving from mutations in the Adenomatous polyposis coli (APC) gene Apc, 
which encodes the tumor suppressor APC protein.  The APC protein has many functions, 
including cell cycle control, cell attachment and cell migration. APC also functions in the β-
catenin destruction complex .  APC has multiple sites for binding to both beta-catenin and axin.  
Axin is a protein that binds to both GSK3 kinase and β-catenin within close proximity to each 
other.  This complex results in downstream phosphorylation events of β-catenin that lead to 
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ubiquitination and degradation, which further controls cell division and differentiation.  This 
mechanism of cell cycle control is often dysregulated in colon cancer cells through mutations in 
Apc (Yang et al., 2006).  However, FAP-specific association only accounts for about 1% of 
colorectal cancers.   
 
Figure 1.4: Vogelstein model of colon cancer induction 
Modified from: http://syscol-project.eu/about-syscol/ 
 
 
The “Vogelstein model” describes the most common genetic mutation sequence over 
time that is associated with colon cancer as follows:  1) inactivating mutations in the Apc gene, 
2) activating mutations in the Kras (Kirsten rat sarcoma viral oncogene homolog) gene, 3) 
inactivating mutations in chromosome 18, including the Dcc gene (deleted in colon cancer) and 
SMAD family members and 4) inactivating mutations in the Tp53 (Tumor protein p53) gene 
(Johnson et al., 2013 and Fearon et al., 1990).  However, dozens of mutations may be detected in 
a given colon cancer tumor sample, with about 5-12 of the mutations being considered critical 
“driver” mutations that modulate on average 12-20 pathways (Johnson et al., 2013 and Leary et 
al., 2008).  Furthermore, the Vogelstein model tends to characterize tumors from the descending 
colon, which accounts for about 80% of colon cancer. 
Colon cancer etiology varies by location with tumors in the ascending colon being 
characterized more often by microsatellite instability, mutations in ß-catenin, Braf (v-raf murine 
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sarcoma viral oncogene homolog B), TgfßIIR (transforming growth factor, beta receptor II) and 
Bax (BCL2-associated X protein), as well as often being preceded by poorly differentiated 
sessile growths, excess mucin production, hyperplastic serrated adenomas and Lynch syndrome.  
Tumors in the descending colon tend to be characterized by chromosomal instability, mutations 
in Apc, Kras, Smad and Tp53, as well as being preceded by benign adenomatous polyps, well-
differentiated, pedunculated tubular adenomas and FAP (Johnson et al., 2013).  70% of sporadic 
colon cancer is associated with mutations in the Apc gene and occur in the descending colon 
(Johnson et al., 2013).  The sporadic colon cancer in the ascending colon tends to 
hypermethylation in promoter regions of the Msh2 (mutS homolog 2) and Mlh1 (mutL homolog 
1) genes, which are associated with DNA mismatch repair mechanisms (MMR) (Johnson et al., 
2013).   
 
 
 
Figure 1.5: Ascending vs. Descending colon cancer 
Modified from: http://www.webmd.com/colorectal-cancer/colonoscopy  
 
 
 
 
 
 
 
 
 
17 
 
4.  Colon Cancer Modifiers and Research Models 
 
4-1 Non-rodent models of colon cancer 
Cancer in the digestive tract has been detected in canines, primates and sheep.  The 
canine presentation of cancer does closely mimic what has been shown in humans concerning the 
specific mutations and molecular pathways involved.  However, the incidence of spontaneous 
cancer in dogs, as well as in primates and sheep, is less than 1% and primarily occurs in the 
small intestine, instead of the colon, as is seen in human patients (Johnson et al., 2013).   
 
4-2  Rodent models of colon cancer 
Mouse models were considered for the dissertation research, due to the biological 
similarities in the immune systems from mouse to human, the routine and ease of use, as well as 
the time efficiency for carcinogenesis models.  The entire mouse genome is mapped and genetic 
manipulation of the mouse genome has become routine.  Furthermore, the mouse strains 
discussed (129 wildtype and Il-10
-/-
 on 129/SvEv genetic background) are well described and 
commonly utilized.  Mice have much shorter life spans than humans, requiring less time for 
cancer to develop, or for testing drug efficiency.   
 
4-2-a  Diet-associated 
 
4-2-a-i  Western diet 
Diet is an environmental factor closely associated with colon cancer.  Although it is 
difficult to control for in human populations, mechanisms underlying its importance can be 
explored using rodent models.  Although the “Westernized diet” is still being standardized in 
research publications, different diet preparations share in common trends of increased fat, 
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increased sugar and reduced fiber.  The AIN76A commercially available diet from Harlan 
Laboratories, has been modified to a “Western diet” that contains an increase in fat (20%), a 
decrease in calcium (0.05%) and a decrease in vitamin D (1000 IU/kg diet).  Exposing mice and 
rats to this diet for 12 weeks was enough to induce hyperplasia within colonic crypts, dysplastic 
crypts and polypoid lesions when fed for 2 years (Newmark et al., 1990; Risio et al., 1996).  
Furthermore, increasing the calcium and vitamin D was enough to prevent colonic tumors.  
Increasing fiber and methyl-donor nutrients, however, failed to rescue the mice from colon 
cancer onset (Richter et al., 1995; Newmark et al., 2009; Johnson et al., 2013).  Furthermore, the 
mRNA transcript profile of Paneth cell markers (normally only found at the bottom of small 
intestinal crypts) increased in intestinal villi and colon crypts with the addition of the Western 
diet to that seen in mice with loss of an allele in the Apc gene, which indicates that diet is 
sufficient to increase risk for colon cancer (Wang et al., 2010).  Dietary components can increase 
risk of colon cancer through affecting bile production and bile components, such as deoxycholic 
acid (DOC), which causes oxidative and nitrosative stress leading to DNA damage and mutations 
associated with colorectal cancer (Bernstein et al., 2011).  Other associations with diet and 
human colon cancer include alcohol (increase risk), animal fats (increase risk), milk (reduced 
risk), Selenium (reduced risk) and vitamin D (reduced risk) (Vargas et al., 2012).  This led me to 
ask the question of whether a dietary supplement of curcumin could effectively be used to limit 
the progression from chronic inflammation to colon cancer. 
 
4-2-a-ii  PhIP (2-amino-1-metyl-6-phenylimidozo [4,5-b] pyridine) 
Another environmental factor associated with colon cancer is PhIP (2-amino-1-metyl-6-
phenylimidozo [4,5-b] pyridine), a heterocyclic amine found in cigarette smoke, diesel fumes 
and cooked meat and fish.  The risk of exposure and production of PhIP increases as the 
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temperature at which meat and fish is cooked increases.  Boiling meat and fish and cooking at a 
lower temperature, even if cooking time is increased, reduces the risk.  N-Hydroxylation of PhIP 
occurs in the liver through phase I hepatic cytochrome P450, mainly by CYP1A2, followed by 
phase II esterification with N-acetyltransferase and N-sulfotransferase.  The resulting 
arylnitrenium ions react with nucleophilic sites on DNA, typically at guanine bases, and form 
DNA adducts, such as dG-C8-PhIP, the most common PHIP-associated DNA adduct (Nakagama 
et al., 2005).  The dG-C8-PhIP DNA adduct has been detected in human colon tissue samples, 
using the 32P-postlabeling, HPLC and an IHC method using an anti-PhIP-adducted DNA 
polyclonal antibody (Nakagama et al., 2005).  PhIP increases the rate of mutation in mammalian 
cells, such as Chinese hamster fibroblasts, as well as in colonic tissue of rats and mice.  PhIP has 
been shown to be carcinogenic in the colon of rats.  PhIP is carcinogenic in the colons of mice 
when used with either Dextran Sodium Sulfate (DSS) treatment or Apc
Min
 mice.  PhIP-induced 
tumors occur in the middle to distal regions of the colon tissue in rodents and primarily have 
mutations in the Cnntb1 and Apc genes (Johnson et al., 2013).  This indicates that food-borne 
carcinogens can greatly increase the risk of colon cancer by affecting colonic epithelium directly.  
Thus, diet is a powerful factor in disease progression.  This dissertation research focuses on 
using the environmental factor of diet as a therapeutic tool to decrease the risk of colon cancer. 
 
4-2-b  Genetics-associated (Apc
Min
 mouse) 
Mouse model systems also exist that closely mimic the human genetic predisposition to 
develop colon cancer due to mutations in the Apc gene, which is a commonly mutated gene in 
colon cancer that is associated with a specific familial syndrome, familial adenomatous polyposis 
(FAP).  FAP characterized by hundreds of polyps along the colon tissue and accounts for about 
1% of colorectal cancers (Johnson et al., 2013).  The homozygous phenotype, or mutations in 
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both alleles, for the Apc gene results is fatal in embryonic mice.  Thus, Apc
Min
 mice are 
heterozygous with “min” standing for multiple intestinal neoplasms and allow for a model 
system of small intestinal polypoid growths.  Tumors form in both the large and small intestines, 
with the greater burden being in the small intestine.  The mutation arises from a T-to-A 
transversion that truncates the APC protein.  This strain is well suited to identify genetic 
modifiers of colon cancer risk, referred to as modifiers of min, or Mom (Johnson et al., 2013).  
While mutations in the Apc gene are commonly found in sporadic human colon cancers, they do 
not account for all colon cancer types and our patient population of interest are patients with a 
history of chronic inflammatory bowel diseases that progress to colon cancer, rather than patients 
with known genetic predispositions, or known familial disorders that make them higher risk for 
colon cancer onset.  Furthermore, Apc
Min
 mice do not live long enough (tend to die by 120 days 
of age) on average to endure a long-term chronic research study (Johnson et al., 2013).  For these 
reasons, the 129/SvEv background IL-10
-/- 
mouse
 
strain was chosen, which more closely models 
the patient population of interest by allowing spontaneous, progressive inflammation to be 
established before induction of the cancer with the chemical carcinogen AOM. 
 
 
4-2-c  Chemically-induced  
 
4-2-c-i  Nitroso compounds 
Chemical carcinogens, such as N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and N-
methyl-N-nitrosourea (MNU, NMU) can be used to induce colon cancer.  Unfortunately, these 
carcinogens cause widespread cancer in various organs, including stomach, small intestine, large 
intestine, kidney, skin, lung, thymus, prostate and breast.  This can be reduced if administered 
rectally, but still affects lung and thymus (Johnson et al., 2013).  Although dietary treatments, 
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such as the 1alpha-hydroxy-24-ethylcholechalciferol vitamin D analogue, have been shown to 
decrease the effectiveness of nitroso compounds to induce carcinogenesis, utilizing a carcinogen 
that is specific to the colon tissue would be especially beneficial. 
 
4-2-c-ii  Azoxymethane 
AOM is a well-established chemical carcinogen of colon cancer in mice and rats and only 
causes tumors in the colon tissue.  AOM is a derivative of 1,2-dimethylhydrazine (DMH) and 
functions as a carcinogen through alkylating DNA.  The chemical AOM gets processed in 
multiple steps and locations.  First, it is processed (specifically through hydroxylation to 
methylazoxymethanol) by cytochrome P450 in the liver.  Then, it is excreted in the bile and 
further processed (into methyldiazonium) by bacteria residing in the colon.  This is the most 
carcinogenic form of AOM.  Because the carcinogenic metabolite is processed in the colon, it is 
active here and causes colon tissue-specific carcinogenesis, with the vast majority of the tumor 
burden occurring in the distal region of the colon where the bacterial burden is highest.  It acts 
through alkylation of DNA (transfer of an alkyl group to a base - most common form of 
alkylation is methylation for DNA), causing base pair mismatches.  The damage leads to poor 
repair and a higher likelihood for further mutations, all of which contribute to the cells gaining 
uncontrolled growth and division properties and, thus, to the onset of cancer (Neufert et al., 
2007).  AOM-associated tumors have the majority of mutations in the Ctnnb1 gene.  These 
mutations affect the N-terminal amino acids of the ß-catenin protein, which results in 
stabilization and of the protein and upregulation of the WNT signaling pathway (Johnson et al., 
2013).  AOM is a well-established and commonly utilized chemical induction of colon cancer 
that makes it ideal for my research.  It can be paired with models that mimic inflammatory bowel 
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conditions, such as the dextran sulfate sodium salt (DSS) treatment model system and the Il10
-/-
 
mice, which have spontaneous, progressive chronic inflammation.  This facilitates research 
concerning colitis-associated colon cancer, which is the disease of interest and focus for my 
thesis. 
AOM is commonly used with DSS, a chemical means of inducing damage to the 
epithelial lining of the gastrointestinal tract, resulting in an ulcerative-colitis type of colitis-
associated colon cancer.  Modulations of the AOM/DSS model vary from a single injection to 
multiple injections and changing the dose and timing of DSS (Neufert et al., 2007).  However, 
this is a harsh treatment of the epithelial lining that recovers when the DSS is removed from the 
mouse’s system.  This dissertation research focuses on a patient population that has spontaneous 
and chronic colitis leading to colon cancer.  AOM used with Il10
-/-
 mice more closely resembles 
a Crohn’s type of colitis-associated colon cancer and is a well established model system in 
scientific literature.  Il10
-/-
 mice are able to survive long enough for long-term cancer studies and 
have a spontaneous, progressive inflammation that responds to treatments known to be effective 
in human patients, such as anti-TNFα.  For these reasons, the AOM-IL-10-deficient mouse 
model of colitis-associated colon cancer (Kanneganti et al., 2011; Uronis et al., 2009) was 
utilized.  Below is a schematic describing the processing of azoxymethane, although it should be 
noted that recent studies suggest that the processing of AOM into the carcinogenic metabolites 
are not as dependent on microbiota as previously thought, as germ free (GF) mice have a much 
greater tumor burden than specific pathogen free (SPF)-housed mice given AOM and DSS (Zhan 
et al., 2013). 
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Figure 1.6: Azoxymethane (AOM) processing.  From:  Neufert et al. 2007.  An inducible model of colitis-associated colon 
cancer.  Nature Protocols 2(8):1998-2004. 
 
 
5.  Chronic inflammation is linked to perturbation of the established gut microbiota 
A long-standing question in CAC research concerns the origin of inflammation.  The 
gastrointestinal tract contains an incredibly complex and symbiotic microecosystem.  The 
microbiota present in the intestines provide essential and non-redundant functions, such as 
fermentation of otherwise nondigestible dietary components and maintaining homeostasis of the 
human metabolism and immune system (Zhu et al., 2011 and Flint et al., 2012).  However, 
perturbations of the microbial communities via diet changes or illness, for example, contribute to 
inflammation that can often become uncontrolled and chronic.  The “keystone pathogen” 
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hypothesis describes a phenomenon where a species of bacteria may have a disproportionately 
large impact on the host environment relative to its low abundance (Hajishengallis et al., 2012), 
as opposed to a single bacterial species becoming the predominant species and initiating tissue 
damage and disease.  The interplay of one or more specific bacterial species with the entire 
commensal bacterial community to cause dysbiosis is illustrated through a study utilizing the 
TRUC mouse model system (Garrett et al., 2010).  The combination of the bacteria Klebsiella 
pneumoniae and Proteus mirabilis failed to induce colitis in germ-free animals, while the 
combination did induce colitis in conventionally housed animals, suggesting a dependence on the 
interaction of these two bacterial species with the commensal microbiota community to induce 
disease.  This indicates that global changes in microbial composition contribute to inflammation, 
which can become sustained in the host.  The risk for colon cancer increases for patients 
diagnosed with chronic inflammatory bowel diseases.  It is estimated that 18% of UC patients 
with a 30-year history of UC will develop colon cancer (American Cancer Society, 2014). 
 
5-1  Assessing Microbial Diversity 
Due to the inability to culture the majority of gut microbiota, culture-independent 
methods of assessing microbial diversity were explored.  A common method is to collect a stool 
sample and sequence a single marker gene that is ubiquitously expressed and which is conserved 
over evolutionary time.  The most common marker gene currently utilized is the 16S ribosomal 
RNA subunit gene (16S rRNA).  This gene has known conserved regions and known variant 
regions, which have unique sequences for each bacterium.  Multiple sequences detected in a 
single stool sample can be tagged and compared to sequences in a reference database, such as 
GreenGenes, to get a more complete understanding of the microbial composition of the 
individual.  Some caveats exist, such as the machine platform used for sequencing.  Some 
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platforms, such as the Illumina, are able to sequence many more sequences for a run than earlier 
technologies, which makes comparing results among publications using different platforms 
inappropriate, as there could be a sampling issue that strongly biases the results.  Furthermore, 
there is some leniency to designing the barcodes that identify the variable regions of 16S rRNA; 
tagged sequences that differ by only a few base pairs may really be the same sequence, just with 
a sequencing/read error.  To allow for this, sequence divergence is generally set slightly lower 
than 100%, typically 97%.  These clusters are assumed to be the same Operational Taxonomic 
Unit (OTU).  The alpha diversity can be calculated, which represents the richness (number of 
taxa) and evenness (distribution of taxa) within each sample.  Beta diversity measures the 
degree of overlap in taxa among samples.  Diversity can be assessed by comparing OTUs or by 
comparing distances of sequences along a reference phylogenetic tree to indicate diversity of 
microbiota within a sample.  Other culture-independent methods involve metagenomics, utilizing 
whole-metagenome shotgun (WMS) sequencing of genomic DNA fragments, as well as 
metatranscriptomics to assess RNA transcripts, metaproteomics to assess proteins and 
metametabolomics to assess small molecule metabolites of microbial communities (Morgan et 
al., 2014). 
Steps of analysis are summarized as follows: 
1. Extract DNA and amplify 16S rRNA with barcoded primers 
2. Pool samples 
3. Sequence in 1 run (MiSeq on Illumina) 
4. QIIME analysis software 
a. Assign reads to samples 
b. Assign sequences from the samples to OTUs 
c. Compute UniFrac distances on a reference phylogenetic tree 
d. Compare alpha diversity: richness (number of taxa) and evenness (distribution of 
taxa) based on OTUs 
e. Compare beta diversity (how much overlap in taxa the samples have) based on 
UniFrac distances. 
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5-2  Microbiota in healthy individuals 
Colonization of gut microbiota in full-term, naturally-delivered, breastfed, and healthy 
human newborns has been demonstrated to occur in steps and is critical to establishing healthy 
immune systems and healthy metabolic programming (Harmsen et al., 2000; Roger et al., 2010; 
Rautava et al., 2012).  Early colonization is by the Firmicutes phylum with aerobic or 
facultatively anaerobic bacteria, such as Staphlococus and Streptococcus.  Bacteria in the 
Actinobacteria phylum colonize next, along with more anaerobic bacteria, which include the 
Bifidobacterium genus.  Next, the Bacteroidetes phylum and then more anaerobes, such as 
Clostridia and Eubacteria.  The composition is beginning to stabilize at one year of age and 
proceeds to stabilize to that of an adult profile by 2-3 years of age (Rautava et al., 2012).   
The majority of gut microbiota cannot be cultured in a lab.  However, of bacteria that can 
be cultured, many studies consistently show that the most common species in adults include 
Bacteroides vulgatus, Eubacterium rectale, Faecalibacterium prausnitzii, Colinsella aerofaciens 
and Ruminococcus bromii (Flint et al., 2012).  Yet, there is not a specific profile of bacterial 
composition identified as “healthy,” as there exists an incredibly diverse array of microbial 
composition profiles among a healthy human population.   
Diet is certainly an influential factor.  Children raised in rural African communities that 
have a primarily plant-based diet high in fiber have an enrichment of the Bacteroidetes phylum 
and a decrease in the Firmicutes phylum, as well as an increased abundance in the Prevotella and 
Xylanibacter genera, compared to European children.  Functionally, this relates to the presence 
of bacteria that can process cellulose and xylan, which were undetectable in European children.  
There was also an increase in short chain fatty acid production in African children, which is 
27 
 
considered protective in the gut and provides energy to colonocytes and liver cells (De Filippo et 
al., 2010). 
While there may not be a core microbial profile that is uniform for all healthy individuals, 
microbiota have a powerful influence over health, as demonstrated in the emergence of fecal 
transplants in clinical practice.  In a clinical trial feasibility study, fecal microbiota transplant 
(FMT) therapy was shown to reduce diarrhea and relapses of Clostridium difficile infections in 
patients that had been poorly responsive to standard of care treatment.  Donor stool was pooled 
from healthy donors and administered either by colonoscopy or nasogastric tube with both 
methods being effective and neither causing adverse effects (Youngster et al., 2014).  Similar 
findings were demonstrated in a study using an acute colitis DSS model in research mice that 
were co-housed.  The mice differed in their genetic background.  One mouse strain was the 
healthy wildtype and one had a genetic mutation in the Tmf (Tata element modulatory factor) 
gene, which encodes a Golgi protein for vesicle tethering to target membranes.  When this is 
mutated, mice produce especially thick mucus and have an altered microbial composition 
compared to wildtype mice.  Additionally, they are resistant to the acute DSS initiation of colitis 
and can transfer this protection to wildtype mice housed in the same cage (Bel et al., 2014).  
Mice readily practice coprophagia, or consumption of feces, and can transfer microbiota through 
that method.  Microbiota are a potentially powerful therapeutic tool.   
This is an emerging field and what is known is that there are differences from healthy to 
diseased individuals, even though this is not standardized.  A dramatic shift in the microbial 
communities is associated with triggering inflammation that can become chronic and contribute 
to sustained diseases.  Furthermore, a loss of richness, or number of different microbial 
taxonomic groups present in an individual, is associated with disease.   
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5-3  Microbiota and gastrointestinal cancers 
Inflammation has an established partnership with carcinogenesis in the intestines 
(Schwabe et al., 2013, Arthur et al., 2013, Chiba et al., 2012, Balkwill et al., 2001, Ullman et al., 
2011 and Lin et al., 2007).  Likewise, microbial pathogens are known to be associated with 
carcinogenesis in the gastrointestinal tract, such as Helicobacter pylori for gastric cancer, 
hepatitis C virus for hepatocellular carcinoma and Streptococcus bovis for Colorectal Cancer 
(Arthur et al., 2013, Chiba et al., 2012, Heidland et al., 2006, Marshall et al., 1995 and Klein et 
al., 1977).  Even microbial products of commensal bacteria, such as CCL5, can contribute to 
inflammation-associated colorectal cancer by promoting aberrant epithelial cell proliferation (Hu 
et al., 2013).  The question arises as to what is the link between microbial composition, 
inflammation and carcinogenesis.  The paradigm is that microbial changes trigger inflammation, 
which, if sustained, leads to carcinogenesis.  However, there has been a shift in the scientific 
dogma due to studies, which indicate that inflammation itself can modulate microbial 
composition and function, increasing the risk for carcinogenesis (Arthur et al., 2013, Morgan et 
al., 2012, Sokol et al., 2008 and Arthur et al., 2012).  Indeed, it is possible that carcinogenesis 
itself can alter microbial composition, although it remains mechanistically unclear whether the 
microbiota affects the carcinogenesis, or the other way around.  Microbial composition is altered 
under cancer conditions versus healthy individuals.  Establishing microbiota in completely germ-
free mice, using a tumor-bearing mouse source, was sufficient to increase their risk of 
carcinogenesis for the chemical carcinogen utilized (Azoxymethane).  Furthermore, this effect 
was negated with the addition of antibiotics
 
(Zackular et al, 2013). 
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5-4  Microbiota and colon cancer 
The microbial composition has been shown to be altered in colorectal cancer patients, 
compared to healthy individuals (Arthur et al., 2013, Sobhani et al., 2011, Wang et al., 2012, 
Sanapareddy et al., 2012, Marchesi et al., 2011 and Kostic et al, 2012).  The microbial 
composition has also been shown to differ significantly between healthy mice and mice with 
colitis.  Furthermore, the microbial richness is reduced during colitis in mice, as well as in 
human patients (Arthur et al., 2013, Uronis et al., 2009, Ott et al., 2004 and Manichanh et al., 
2006).  These studies were done with mice bred in a completely germ-free (GF) facility and 
transferred to a specific-pathogen free facility (SPF) for the duration of the studies.  Interestingly, 
although changes in commensal bacteria composition were associated with colitis and 
carcinogenesis, commensal bacteria also play a significant role in protection from inflammation 
and carcinogenesis.  Using an AOM/DSS model, when mice are bred in an SPF facility, 
compared to GF, they have fewer and smaller tumors, decreased epithelial proliferation and less 
delay in intestinal epithelial repair.  Recolonization of GF mice with commensal bacteria from 
SPF-bred mice lessened the severity of the disease
 
(Zhan et al., 2013).  The commensal 
microbiota benefits the host by synthesizing essential vitamins, generating various nutrients from 
complex dietary carbohydrates, educating the mucosal immune system and competing with 
invading pathogenic organisms (Arthur et al., 2013, Chiba et al., 2012, Hooper et al., 2001 and 
Lozupone et al., 2012).  While the commensal microbiota serve many protective roles and no 
single type of bacteria has been absolutely linked to colorectal cancer, it has an undeniable 
association with disease progression due to changes in the overall composition, which implies 
that it could, in turn, have an effective role in disease prevention for future therapeutics. 
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Table 1.1:  Specific changes in microbial composition during colon cancer 
 
Gut microbiota Effect Model system Reference 
B. vulgatus 
increase efficacy of Azoxymethane 
(AOM)-induced colon cancer 
mice (IL10 deficient), mono-
associated in germ free 
facility and compared to SPF-
housed 
Uronis et al., 
2009 
E. coli 
increased abundance in colon cancer 
patient biopsies biposies from human patients 
Martin et al., 
2004 
E.coli 
promote invasive carcinoma during AOM-
induction colon cancer mice (IL10 deficient) 
Arhur et al., 
2012 
E. faecalis 
induce chromosomal instability 
(aneuploidy and tetraploidy) in colonic 
epithelial cells 
cells: HCT116, RKO and 
YAMC 
Wang et al., 
2008 
enterotoxigenic 
B. fragilis 
induce colonic tumors, IL-17-dependent 
mechanism 
mice (Multiple intestinal 
neoplasia - Min) 
Wu et al., 
2009 
Fusobacterium 
genus 
increased abundance in rectum of colon 
cancer patients human rectum tissue biopsies 
McCoy et al., 
2013 
H. hepaticus 
increase efficacy of Azoxymethane 
(AOM)-induced colon cancer mice (BALB/c-IL10 deficient 
Nagamine et 
al., 2008 
L. casei, L. 
acidophilus 
protective, decrease activity of beta-
glucourinodase, azoreductase and 
nitroreductase 
rats, measured for free amines 
in diet after administration of 
probiotics 
Goldin et al., 
1984 
L. acidophilus 
protective, decrease activity of beta-
glucuronidase and nitroreductase humans, dietary supplement 
Goldin et al., 
1980 
S. bovis 
increased abundance (p value <0.001 
compared to healthy controls) in patients 
with carcinoma in the colon 
human patients with colon 
carcinoma 
Klein et al., 
1977 
Prevotella genus 
(Bacteroidetes 
phylum) 
increased abundance (p value 0.009) in 
human colon cancer patients 
stool sample prior to 
colonoscopy 
Sobhani et al., 
2011 
Coriobacteria, 
Roseburia, 
Fusobacterium, 
Faecalibacterium 
genera increase in tumors of colon cancer patients 
human, tumor vs. adjacent 
tissue 
Marchesi et 
al., 2011 
Bacteroides, 
Odoribacter,  
Akkermansia 
genera 
increased abundance in mice with tumors, 
microbiota from these mice into germ-free 
resulted in increased tumor burden 
mice (C57BL/6), AOM/DSS 
model 
Zackular et al., 
2013 
Lactobacillus 
S06, E. 
aerofaciens 
increased abundance in patients with low 
risk for colon cancer 
humans with colonic polyps 
(stool samples) 
Moore et al., 
1995 
B. vulgatus, 
Eubacterium 
spp., 
Ruminococcus 
spp., S. hansenii, 
Bifidobacterium 
spp., F. 
prausnitzii 
increased abundance in patients at high 
risk for colon cancer 
humans with colonic polyps 
(stool samples) 
Moore et al., 
1995 
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6.  Curcumin: bridging the therapeutic gap between inflammation and colorectal 
 carcinogenesis 
This thesis addresses the potential roles of Curcumin to prevent major perturbations in 
the microbial communities, as well as to maintain homeostasis of the immune system.  Curcumin 
is a component of the turmeric cooking spice, which is isolated from the rhizome of the Curcuma 
Longa plant.  It is an incredibly promising compound for therapeutic uses, due to its ability to 
regulate inflammation, oxidation and carcinogenesis.  The low toxicity of this compound 
provides a promising medicinal alternative for patients suffering from colitis-associated 
colorectal cancer.  Curcumin is tolerated well in humans at doses as high as 12 g/day/adult
 
(Lao 
et al., 2006). 
 
 
6-1  Structure and components 
Curcumin is the most abundant and most bioactive analogue component of curcuminoids, 
comprising of about 77% of the total.  Demethoxycurcumin comprises about 17% and 
bisdemethoxycurcumin comprises the remaining 3%.  Each curcuminoid shares a common 
aromatic ring, but differs in the methoxy substitutions of aryl moieties.  Curcumin is a 
hydrophobic polyphenol bis α,ß unsaturated ß-ketone known as diferuloylmethane, or 1,7-bis-(4-
hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione.  It is a linear diarylheptanoid with 2-oxy-
substituted aryl moieties connected through a 7-carbon chain (Soni et al., 2012).  In addition, 
curcumin has bioactive degradation products with the most common being ferulic acid and 
vanillin (Ji et al., 2014). 
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Figure 1.7: Structure of curcumin.  From: Kawamori et al. 1999.  Chemopreventive Effects of Curcumin, a Naturally Occuring 
Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer.  Cancer Research 59:597-601. 
 
 
6-2  Targets of curcumin 
Curcumin is able to regulate a large array of targets, including tumor suppressor genes 
(Rb, p53 and PTEN), growth factors (TGF-β, EGF and p21), kinases (AMPK, Cyclin D and 
Akt), transcription factors (NF-κB, STAT-3, β-catenin and AP-1), enzymes (COX2, iNOS and 
MMPs), inflammatory cytokines (IL-6, IL-1β, TNF-α and MCP), Apoptotic genes (Bcl-2, Bak, 
Bax and Caspase 8) and Oncoproteins (c-Myc, Ras and Fas)
 
(Ramamoorthi et al., 2014).  Thus, 
curcumin is an incredibly promising compound for cancer therapeutics, as it can inhibit cell 
growth cycle and survival mechanisms. 
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Figure 1.8: Targets of curcumin 
Modified from Ramamoorthi, G. and N. Sivalingam.  2014.  Molecular mechanism of TGF-ß signaling pathway in colon 
carcinogenesis and satus of curcumin as chemopreventive strategy. Tumor Biology ePub ahead of print. 
 
 
6-3  Functions of curcumin 
Mechanistically, curcumin can limit colon cancer progression through increasing mRNA 
expression and protein levels of the DNA damage-inducible gene (DDIT3), resulting in 
induction of chromatin condensation and DNA fragmentation.  Furthermore, Curcumin promotes 
cell cycle growth arrest through regulation of c-myc, cyclin D, Cyclin B and cell division control 
2 (CDC2) (Shishodia et al., 2007).  Curcumin can induce apoptosis in colorectal cancer cells 
(Caco2) through inhibition of the Polyisoprenylated methylated protein methyl esterase 
(PMPMEase) enzyme
 
(Amissah et al., 2013).  However, the ability of curcumin to affect the gut 
microbiota is unknown and, thus, is an exciting frontier of research in colitis-associated 
colorectal cancer. 
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6-4  Bioavailability of curcumin 
Curcumin is considered poorly absorbed, rapidly metabolized and rapidly eliminated with 
low aqueous solubility (Ji et al., 2014).  A study from our lab detected through HPLC analysis 
significant amounts (ranging from 1.54 ± 0.2 mM to 7.54 ± 0.3 mM) of unmetabolized curcumin 
in the colon lumen for mice fed curcumin in their diets with doses ranging from 0.1% to 1% 
(Larmonier et al., 2008).    Nevertheless, it remains highly effective and much effort has been 
placed into increasing its bioavailability.  Bioavailability increases 154% when curcumin is 
administered concomitantly with the adjuvant piperine, an inhibitor of hepatic and intestinal 
glucouronidation, to human patients and research rodents.  Clearance time of curcumin is 
significantly reduced with piperine and serum concentration is significantly increased, as is the 
time to maximum serum concentration (Shoba et al., 1998).  There is a clinical trial actively 
recruiting for patients to assess bioavailability of curcumin using plant exosomes as a delivery 
method (clinicaltrials.gov ID:NCT01294072).  Furthermore, curcumin has been explored for use 
in increasing bioavailability of nanoparticle-based therapeutics against colorectal cancer.  
Curcumin was shown to enhance uptake and mucoadhesiveness of the nanoparticles in colorectal 
cancer cells in an ex vivo study.  The curcumin-loaded nanoparticles also promoted cell cycle 
arrest in the G2/M phase and reduced overall cell viability of the cancer cells
 
(Chuah et al., 
2014).  Apart from muco-adhesiveness, the targeting and drug delivery of curcumin has been 
explored for colorectal cancer research.  Curcumin-loaded lipid-polymer-lecithin hybrid 
nanoparticles were synthesized with ribonucleic acid Aptamers against the epithelial cell 
adhesion molecule (Apt-CUR-NP) in order to deliver curcumin to colorectal adenocarcinoma 
cells.  The Apt-CUR-NP bioconjugates demonstrated increased cytotoxicity of the HT29 
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colorectal cancer cell line, as well as improved binding of Curcumin to the target when compared 
to free unbound Curcumin, or particles made with a control Aptamer
 
(Li et al., 2014).   
 
6-5  Curcumin and cancer therapeutics 
Apart from the numerous roles of curcumin to affect specific targets to reduce 
inflammation, oxidative stress and carcinogenesis, curcumin has been shown to enhance the 
effectiveness of cancer therapeutics, such as 5-fluorouracil (5-FU).  This is especially beneficial 
because patients can develop a resistance to 5-FU.  When cells were treated concomitantly with 
5-FU and curcumin, those cultures demonstrated cell cycle growth arrest, increased apoptosis 
and a decrease in cell surface markers associated with cancer stem cells
 
(Shakibaei et al., 2014).  
Many clinical trials have been completed, or are ongoing that address the toxicity of curcumin 
(ClinicalTrials.gov ID: NCT00027495, NCT01859858), as well as its effectiveness when used 
with other chemotherapeutic agents (NCT01490996) or as a colon cancer preventative agent 
(NCT00003365, NCT00973869).  
 
6-6  Curcumin effects on bacteria 
Curcumin has been reported to work as an antimicrobial agent.  It has been shown to 
inhibit biofilm formation when administered to K. pneumoniae in vitro (Magesh et al., 2013).  
The combination of curcumin and cinnamaldehyde also resulted in inhibition of biofilm 
formation, inhibition of planktonic culture growth and disruption of bacterial membranes of S. 
epidermidis in vitro (Sharma et al., 2014).  Through a macrodilution broth susceptibility method, 
curcumin was shown to reduce bacterial growth of numerous strains, including methicillin-
sensitive S. aureus, methicillin-resistant S. aureus, E. faecalis, B. subtilis, P. aeruginosa, E. coli 
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and K. pneumoniae (Gunes et al., 2013).  Furthermore, curcumin can have an inhibitory effect on 
pathogenic products of bacteria.  Curcumin was shown to inhibit the Sortase A enzyme, which 
affects the cariogenicity of S. mutans in dental caries (Hu et al., 2013).  Besides inhibiting 
bacterial growth, curcumin has also been shown to limit bacterial adhesion and RTX toxin 
binding of the bacterial pathogen V. vulnificus and protected research mice from septicemia (Na 
et al., 2011).  The effects of curcumin on bacteria in culture are well established, while its effect 
on gut bacteria, specifically, is understudied and its effect on global microbial composition in the 
context of colitis-associated colon cancer remains unknown and is the focus of this dissertation.   
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7.  Summary 
Curcumin serves an important function in regulation of intestinal inflammation and colorectal 
carcinogenesis.  The use of curcumin as a possible therapeutic and/or preventive agent for 
colonic inflammation and cancer, is a promising area of research in the context of modulation of 
the gut microbiota during colitis-associated colon cancer, as this is a novel study in the field.  
Hypothesis: curcumin will modulate the bacteria of AOM-treated chronically-inflamed Il10
-/-
 
mice to become similar in composition to that of healthy, untreated wildtype mice, thus restoring 
the health of the mice. 
 
The main goal of the dissertation research is to identify a chemopreventive strategy that restores 
a healthy microbiota through the dietary addition of curcumin. 
 
The research aims are twofold: 
A) To optimize the methodology of colonic microbiota analyses based on Illumina (MiSeq) 
16S ribosomal RNA gene sequencing with the goal of adapting this cost-effective next 
generation sequencing strategy for detailed taxonomic analyses of complex microbial 
communities in the colon. 
 
B) To evaluate the chemopreventive effects of dietary curcumin on the development and 
progression of colon cancer and the associated changes in composition of luminal and 
mucosal colonic microbiota. 
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CHAPTER 2:  DATA ANALYSIS 
 
A.  METHODS 
Curcumin 
98.05% pure curcumin, free of contaminating curcuminoids (demethoxy-curcumin and 
bis-demethoxy-curcumin) was obtained from ChromaDex (Irvine, CA).  Curcumin was 
incorporated into NIH-31 modified open formula at 0.05, 0.1, 0.5 and 1% and pelleted by Harlan 
Teklad (Madison, WI).  
 
Experimental animals 
Specific pathogen-free wild type (WT) 129/SvEv mice and germ-free Il10
-/- 
mice on the 
same genetic background were originally obtained from the National Gnotobiotic Rodent 
Resource Center at the University of North Carolina, Chapel Hill and transferred to a 
conventional animal facility at the University of Arizona Health Sciences Center. Sentinel mice 
were routinely monitored and determined as free from common murine pathogens (MHV, MPV, 
MVM, TMEV, Mycoplasma pulmonis, Sendai, EDIM, MNV, ecto- and endoparasites). All 
animal protocols and procedures were approved by the University of Arizona Animal Care and 
Use Committee.  
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AOM/ Il10
-/-
 model:  
We utilized a well-documented model to study the development of colitis-associated 
colon cancers in IL-10 deficient mice (Kanneganti et al., 2011; Uronis et al., 2009). This protocol 
is based on the use of the mutagenic agent, AOM, which exerts colonotropic carcinogenicity. 
The advantage of using AOM is that that it does not represent by itself the final carcinogenic 
metabolite.  AOM requires further stepwise activation after intraperitoneal injection, which 
includes a hydroxylation step mediated by cytochrome p450 in the liver and therefore limits 
personnel exposure to the carcinogen. In addition AOM-induced carcinogenesis includes high 
potency and reproducibility with a simple mode of application. Tumors induced by AOM are 
present in the distal colon, which resembles the predominant localization of spontaneous CRC 
reported in human patients. Repeated intraperitoneal administrations of AOM (10mg/kg) were 
given once per week for six weeks to initiate tumorigenesis. AOM administration began at age 
10 weeks to allow for colitis to develop spontaneously in the IL-10 deficient mice. 
The analysis of tumor development can be performed by identification of tumor load and 
histopathological analysis. 
 
Histology and scoring: 
Proximal and distal colons from WT and Il10
-/-
 mice on different curcumin diets were 
harvested and fixed in 10% neutral buffered formalin
 
(Fisher Scientific, Tustin, CA). Fixed 
tissues were then embedded
 
in paraffin, and 5-µm-thick tissue cuts were stained with
 
hematoxylin and eosin (H&E) for light microscopic examination.
 
Sections were graded by a 
veterinary pathologist blinded to
 
the study design according to previously published criteria 
(Kiela 2004).
 
 
40 
 
 
Immunohistochemistry: 
Sections of proximal and distal colon were prepared as above.
 
Tissues were harvested, 
fixed in 10% neutral buffered formalin for 24 hours, processed and embedded in paraffin.  
Routine hematoxylin and eosin (H&E) stains were performed on sections of tissue cut to a 
thickness of 3 microns from the formalin fixed, paraffin embedded (FFPE) blocks.  
Immunohistochemistry (IHC) of a rabbit monoclonal antibody to Beta Catenin clone E247 
(AbCam) was performed using human colon cancer tissues as the positive tissue controls. IHC of 
Ki67 was performed using a rabbit polyclonal antibody (#NCL-Ki67p, Leica Biosystems GmbH, 
Nussloch, Germany), using human tonsil tissue as a positive control. Tissue sections were 
stained with a Discovery XT Automated Immunostainer (Ventana Medical Systems, Inc., 
Tucson, AZ; VMSI) using VMSI validated reagents for deparaffinization, cell conditioning 
(antigen retrieval with a borate-EDTA buffer), primary antibody staining, detection and 
amplification using a biotinylated-streptavidin-HRP and diaminobenzidine (DAB) system and 
hematoxylin counterstaining.  Following staining, slides were dehydrated through graded 
alcohols to xylene and coverslipped with mounting medium.  
 
Images were captured using an Olympus BX50 microscope, and an Olympus DP72 
camera equipped with CellSens
® 
imaging software. All images were standardized for light 
intensity and white balance.  Microphotographs were taken with a 40x objective for all treatment 
groups stained with antibodies to Beta Catenin and Ki-67. An experienced clinical pathologist 
performed the IHC analyses.  Analysis of Beta catenin was expressed using pathology long 
scores. The long scores represent staining intensity ranging from 1+ - 3+ and a percentage of 
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positively stained cells ranging from 1-100%.  Long scores were calculated by multiplying the 
intensity by the percentage. The long score minimum is 1 and the long score maximum is 300.      
 
Real-time RT-PCR: 
Real-time RT-PCR was used to evaluate mucosal expression of TNF-α, IFNγ, IL-6, IL-
1ß, IL-17, IL-12p40, IL-23 mRNA. Total RNA was isolated from mouse distal colon using 
TRIzol reagent (Invitrogen, Carlsbad, CA). 250ng of total RNA was reverse-transcribed using 
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Subsequently, 20 μl of the PCR reactions 
were set up in 96-well plates containing 10 μl 2x IQ Supermix (Bio-Rad), 1 μl TaqMan® 
primer/probe set (ABI, Foster City, CA), 2 μl of the cDNA synthesis reaction (10% of RT 
reaction) and 7 μl of nuclease-free water. Reactions were run and analyzed on a Bio-Rad iCycler 
iQ real –time PCR detection system. Data were analyzed by using the comparative Ct method as 
means of relative quantification, normalized to an endogenous reference (TATA Box Bonding 
Protein, TBP or glyceraldehyde 3-phosphate dehydrogenase, GAPDH) and relative to a 
calibrator (normalized Ct value obtained from control mice) and expressed as 2
-C
t (Applied 
Biosystems User Bulletin #2: Rev B “Relative Quantification of Gene Expression”). 
 
Bacterial DNA processing: 
Fecal samples were collected fresh once per month from individual mice directly into 
sterile Eppendorf tubes and stored at -80°C until processing.  For processing, frozen stool 
samples were individually placed into an Eppendorf tube containing autoclaved zirconium beads, 
lysis buffer (100mM NaCl, 10mM Tris, 100mM EDTA and 0.2mg/ml Proteinase K) and a 
solution of 20% DNAse-free SDS (Sodium dodecyl sulfate) and incubated for 2 hours.  The 
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samples were then exposed to 24:24:1 Phenol:Chloroform:IAA (Ph 8.0, lowest phase) and placed 
into an automatic bead beater machine on high for 2 min, than centrifuged (8,000 rpm for 3 
min.).  The aqueous phase was collected and mixed again with 1:1 Phenol:Chloroform and 
centrifuged (13,000 rpm, 3 min.).  The aqueous phase was collected, exposed to -20°C 
isopropanol with 1:10 3M sodium acetate and incubated at 4°C for 20 min.  The samples were 
centrifuged (13,000 rpm for 20 min. at 4°C) and excess supernatant was discarded.  The 
remaining pelleted material in the tube was washed with cold (4°C) 100% molecular grade 
ethanol and centrifuged (13,000 rpm for 5 min. at 4°C).  Excess supernatant was discarded and 
the remaining pelleted material was allowed to dry and then re-suspended in TE (Tris-EDTA, pH 
8.0) buffer. 
 
Generation of 16S amplicon library and MiSeq sequencing 
The V4 hypervariable region of the 16S rRNA gene was amplified using barcoded PCR 
with 515F and 806R primers following the Earth Microbiome Project protocol (Caporaso et al., 
2012) and quantified using a Nanodrop instrument.  Sequencing was performed at Argonne 
National Laboratories on an Illumina MiSeq (Serial # M02149) using the MCS (MiSeq Control 
Software) version 2.2.0. The data generated in this study will be available in the QIIME DB 
pending publication. 
 
QIIME analysis of microbial diversity: 
The sequence data was analyzed using QIIME 1.7.0-dev (Caporaso et al., 2010). 
 Sequences were assigned to clusters of 97% similarity using QIIME’s uclust-based (Edgar et al., 
2010) open-reference OTU picking protocol with the Greengenes 13_5 reference sequence set 
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(McDonald et al., 2012). The centroid of each OTU was chosen as the representative sequence 
for the OTU. The representative sequences were aligned with PyNast (Caporaso et al., 2010) and 
the trees were constructed with FastTree(4) for phylogenetic calculations. Beta-diversity 
calculations were performed using weighted and unweighted-unifrac metrics(Lozupone et al., 
2005) as implemented in QIIME(Caporaso et al., 2010). Alpha diversity metrics were calculated 
using whole tree phylogenetic diversity (Faith et al., 1992) and chao1 (Chao et al., 1984) as 
implemented in QIIME.   
 
Statistical Analysis: 
Statistical significance (for non-sequencing data) was determined by the analysis of 
variance (ANOVA) followed by Fisher PLSD post-hoc test with StatView software package 
v.4.53 (SAS Institute, Cary, NC). Data were expressed as mean ± standard error of mean. Non-
parametric paired t-tests were done using Excel software.   
Statistical significance (sequencing data) was determined by non-parametric paired t-test 
for the alpha diversity analysis comparing different OTUs in samples, compared using 1000 
permutations.  Differences among groups within beta diversity were calculated using ANOSIM 
(Analysis of Similarity) using 1000 permutations for the calculation of R-values.  The 
Bonferroni-corrected test was also used for beta diversity multivariate analysis comparing 
different taxa associated with OTUs among groups of samples, as well as for PICRUSt-derived 
data.  Taxonomic data was further expressed as mean ± standard deviation and non-parametric t-
tests were done using Excel software where indicated.   
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B.  RESULTS 
 
1. Il10-/-/AOM Colitis-associated colon cancer mouse model system 
Using a colitis-associated colon cancer mouse model system, Il10
-/-
 mice and the 
wildtype control mice were allowed to age to 10 weeks by which point the Il10
-/-
 mice develop a 
spontaneous and progressive colitis (Kühn et al., 1993 and Gomes-Santos et al., 2012).  We fed 
the wildtype and the chronically inflamed Il10
-/-
 mice with curcumin in their pelleted diets 
(prepared by Harlan Laboratories, Table 2.1) at the following doses: 0% (control diet), 0.05%, 
0.1%, 0.5% and 1%.  These mice were injected with either a carcinogen, Azoxymethane (AOM), 
or a placebo, Phosphate Buffered Saline (PBS) (Fig. 2.1A).  There were six mice in each group 
with a total of 120 mice (Fig. 2.1B). 
  
45 
 
 
 
 
Figure 2.1: Experimental setup.  Il10-/- mice and wildtype control mice were arranged in groups of 6 for each curcumin diet 
dose: 0%, 0.05%, 0.1% and 0.5% (1B) and maintained until 10 weeks of age to allow development of colitis in the Il10-/- mice.  
Mice were given either a Phosphate buffered saline placebo injection or an Azoxymethane injection once per week for 6 weeks 
and monitored for an additional 20 weeks to allow induction of tumors (1A). 
Table 2.1: Components of base diet.  Curcumin diets were produced by Harlan Laboratories, using the standard 7013, NIH-31 
diet as a base.  The full table is available online through Harlan. 
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2.  Curcumin increases survival of Il10
-/-
 chronically-inflamed mice, but becomes toxic at 
 very high doses when administered with Azoxymethane carcinogen 
 We first assessed whether curcumin negatively affects survival in a non-cancer context.  
Curcumin has an overall survival benefit for Il10
-/-
 mice on diets 0.05% to 1%.  Il10
-/-
 mice on 
regular control diet had ~83% survival.  However, Il10
-/-
 mice on curcumin diets at doses 0.05% 
to 1% had 100% survival (Fig. 2.2A), indicating a survival benefit of curcumin on chronically-
inflamed mice. 
When mice were injected with the AOM carcinogen, survival decreased for both the 
wildtype and Il10
-/-
 mice on the highest dose (1%) of curcumin.  Two of the six wildtype mice 
did not survive and none of the Il10
-/-
 mice survived on the 1% curcumin diet when administered 
with the carcinogen (Fig. 2.2B).  Due to the toxicity and poor survival of the animals in the 1% 
AOM group, we excluded them from further analysis. 
Curcumin is currently used in clinical trials and is not FDA regulated, as it is considered 
a dietary supplement (ClinicalTrials.gov ID: NCT00027495, NCT01859858, NCT00003365, 
NCT00973869 and NCT01490996).  It has been shown to be well tolerated in large doses in 
healthy individuals (Lao et al., 2006).  Our results in mice correspond to those findings for the 
placebo (PBS-injected mice) groups.  However, the addition of carcinogen and a high dose of 
curcumin (1%) drastically reduce survival in both genotypes, particularly for the chronically 
inflamed mice.  This needs to be carefully considered when choosing doses for patients with 
chronic inflammatory bowel diseases or colitis-associated colon cancer. 
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Figure 2.2: Survival assessment.  Survival of the Il10-/- mice and wildtype control mice was assessed by generating a Kaplan-
Meier curve using the GraphPad Prism software version 5.0a.  1 of 6  placebo-injected Il10-/- mice died in the 0% curcumin diet 
group.  All other placebo-injected mice in every group had 100% survival (2A). 3 of 6 carcinogen-injected  Il10-/- mice died in 
the 0% curcumin diet group.  2 of 6 carcinogen-injected wildtype mice and 6 of 6  Il10-/- mice died in the 1% curcumin diet 
group.  All other carcinogen-injected mice had 100% survival (2B). 
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3.  Curcumin reduces hyperplasia in AOM-treated Il10
-/-
 mice 
We assessed the colon at the gross tissue level upon sacrifice of the animals and saw a 
reduction in weight/length ratios, which are a measure of hyperplasia in colonic tissue that 
corresponds well to histologic scoring (Ostanin et al., 2009).  This reduction increases as the 
dose of curcumin increases, indicating a beneficial role of curcumin and a dose-dependent 
mechanism (Fig. 2.3). 
 
Figure 2.3: Hyperplasia assessment in gross colonic tissue.  Colons of mice were removed upon euthanasia at the end of the 
study (week 20) and flushed with sterile Phosphate Buffered Saline (PBS) to remove excess content in the lumen of the colon. 
The length (cm) of the colon and the weight (mg) were measured.  Ratios represent weight/length.  Groups were considered 
statistically different by a p value < 0.05 using the Student’s t-test (Excel software) to assess in pairs the 0% diet to each diet 
concentration within a group.  Exact p values are as follows.  WT(PBS) 0% to 0.05%, p = 0.2218; 0% to 0.1%,  p = 0.5104; 0% 
to 0.5%, p = 0.1302.  Il10-/-(PBS) 0% to 0.05%, p = 0.2109; 0% to 0.1%, p = 0.2367; 0% to 0.5%, p = 0.0673.  WT(AOM) 0% to 
0.05%, p = 0.0006; 0% to 0.1%, p = 0.0103; 0% to 0.5%, p = 0.0001.  Il10-/-(AOM) 0% to 0.05%, p = 0.0064; 0% to 0.1%, p = 
0.0015; 0% to 0.5%, p = 0.0000.  
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4.  Curcumin reduces histological scoring in AOM-treated Il10
-/-
 mice in a dose-dependent  
manner 
 We next wanted to compare the whole tissue hyperplasia assessment to histological 
scoring.  Curcumin reduces the overall histological score (Table 2.2) in the distal region of the 
colon for the AOM-treated Il10
-/-
 mice fed the 0.1% and 0.5% curcumin diets compared to the 
AOM-treated Il10
-/-
 mice fed the 0% curcumin control diet.  Likewise, curcumin reduces the 
overall histological score in the distal region of the colon for AOM-treated wildtype mice fed the 
0.5% diet (Fig. 2.4B).  We see a similar trend for the proximal region of the colon (Fig. 2.4A).  
This is demonstrated in representative pictures of the distal colonic tissue Hemotoxylin and 
Eosin (H&E) staining of AOM-treated mice (Fig. 2.4C).  While the AOM-treated wildtype and 
Il10
-/-
 mice developed tumors, they also had areas of healthy epithelium.  The other curcumin 
diets for the AOM-treated mice in both the distal and proximal regions of the colon trended 
towards a reduction compared to the AOM-treated 0% curcumin control group, but did not reach 
statistical significance.
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Score Cancer Inflammation Colitis Description Infiltrates 
Crypt 
Hyperplasia 
0  none  none  none  none  none 
1  none  mild  multifocal infiltrates  lymphocytes, plasma cells   none 
2  none  mild  subacute multifocal 
 predominantly 
lymphocytic  none 
3  none  mild  subacute multifocal to coalescing 
 predominantly 
lymphocytic  mild  
4  none  mild  subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  mild  
5  none  moderate  subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  moderate 
6  none  moderate 
 subacute multifocal to coalescing, 
ulcerations 
 mixed lymphocytic and 
neutrophilic  moderate 
7  none  moderate  subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  moderate 
8  none  severe 
 subacute multifocal to coalescing, 
ulcerations 
 mixed lymphocytic and 
neutrophilic  severe 
9  none  severe  subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  severe 
10 
 
present  mild   subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  mild  
11 
 
present  moderate  subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  moderate 
12 
 
present  severe  subacute multifocal to coalescing 
 mixed lymphocytic and 
neutrophilic  severe 
 
Table 2.2:  Histological scoring key.  A description of histological scores is shown with a higher score representing increasing severity of hyperplasia, colitis and/or cancer.  
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Figure 2.4: Histological scoring.  Colons of mice were removed upon euthanasia at the end of the study (week 20) and flushed 
with sterile Phosphate Buffered Saline (PBS) to remove excess content in the lumen of the colon, cut longitudinally and rolled 
with the nitrocellulose paper into a “swiss roll,” fixed in 10% neutral buffered formalin for 24 hours and processed for 
embedding in paraffin.  Hematoxylin and eosin (H&E) stains were performed on sections of tissue cut with a width of 3 microns 
from the formalin fixed, paraffin embedded (FFPE) blocks. The histological assessment and scoring was performed by a 
pathologist (blinded to the study groups) and scores are represented for proximal colon (4A) and distal colon (4B).  
Representative pictures of the stained sections used for scoring are shown for the distal colon (4C). 
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5.  Curcumin reduces tumor burden in AOM-treated Il10
-/-
 mice 
We assessed the mice for tumor burden and saw a reduction for the AOM-treated Il10
-/-
 
mice, as well as for the wildtype control mice (Fig. 2.5A and 2.5B).  Macroscopically, we could 
not visually detect tumors in the PBS-treated Il10
-/-
 mice, although histological assessment 
detected spontaneous tumors within the colonic tissue.  Wildtype mice had no spontaneous 
tumors.   
The use of AOM to induce colon cancer is a well-described method that promotes tumors 
primarily in the distal region (Neufert et al., 2007).  Tumors of the AOM-treated Il10
-/-
 mice 
were primarily in the distal region of the colon, while spontaneous tumors of the PBS-treated 
Il10
-/-
 mice were exclusively in the proximal region of the colon.  AOM-treated wildtype mice 
had tumors exclusively in the distal region of the colon.   
Curcumin did not reduce the likelihood of Il10
-/-
 mice to spontaneously develop tumors 
(2.5B).  This suggests that the efficacy of this treatment may depend on the mechanism of 
carcinogenesis, as well as the genetic background of the host.   
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Figure 2.5: Tumor burden.  Colons of mice were removed upon euthanasia at the end of the study (week 20) and flushed with 
sterile Phosphate Buffered Saline (PBS) to remove excess content in the lumen of the colon, cut longitudinally and any tumors 
present were recorded for area, distance from proximal end, and abundance.  Average numbers of macroscopic tumors per mouse 
in a group are represented with an insert giving an example of what was considered a tumor (5A).  A pathologist, blinded to the 
study groups, determined presence of tumors histologically on H&E stained tissue sections (5B).  It is important to note that the 
average number of macroscopic tumors per mouse for the AOM-treated Il-10-/- mice is an underestimate as this group had two 
mice with tumor burden classified as “too many to count” (above 10 ten tumors, numerous and tiny) and were assigned an 
arbitrary number of “10” for the purposes of calculation. Numbers of mice with macroscopic tumors are as follows: PBS-treated 
Il10-/- mice + 0.1% (1 of 6); AOM-treated WT mice + 0% (2 of 6); AOM-treated Il10-/- mice + 0% (3 of 6), 0.05% (5 of 6), 0.1% 
(4 of 6) and 0.5% (0 of 6).  Numbers of mice with tumors assessed histologically are as follows: PBS-treated Il10-/- mice + 0.05% 
(5 of 6), 0.1% (4 of 6) and 0.5% (1 of 6); AOM-treated WT mice + 0% (2 of 6); AOM-treated Il10-/- mice + 0% (4 of 5). 
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6.  Curcumin reduces aberrant localization of beta-catenin in AOM-treated Il10
-/-
 mice 
 We next assessed the general expression and localization of beta-catenin, a protein that 
functions in cell-cell adhesion, gene transcription, cell division and differentiation and which is 
commonly mutated in colon cancer (Miyaki et al., 1999).  We chose the 0.5% diet for analysis, 
as it was the most effective dose in tumor reduction.  AOM-treated Il10
-/-
 mice without curcumin 
in the diet had tumors and increased expression of beta-catenin and localization was much more 
varied, being located at the nucleus, cytoplasm and membrane (Fig. 2.6A).  Compared to the 
control diet (0% curcumin), the Il10
-/-
 mice on the 0.5% curcumin diet showed increased 
localization of beta-catenin to the membrane, as we see in healthy tissue and the PBS-treated 
animals that did not produce spontaneous tumors (Fig. 2.6B).  The histological long scores are 
reported (Table 2.3).  While curcumin did not reduce the incidence of spontaneous tumors, beta 
catenin is localized to the membrane in the epithelium of the tumor in the only PBS-treated + 
0.5% curcumin Il10
-/-
 mouse that developed a spontaneous tumor (Fig. 2.6C).  Some areas of 
that sample also expressed beta-catenin in cytoplasmic or nuclear regions.  However, the 
membrane localization in 2.6C demonstrates a very different morphology than the AOM-induced 
tumors shown in 2.6A.  This indicates a beneficial effect of curcumin on beta-catenin 
localization.  
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     Table 2.3 
Beta-catenin IHC scoring (Long Scores) 
 Score Tumor(s) 
     
0% w AOM-WT 300 Tumor 
0% w PBS-WT 100 No Tumor 
0% w AOM (IL10) 300 Tumor 
0% w PBS (IL10) 200 No Tumor 
.5% w AOM -WT 200 No Tumor 
.5% w PBS-WT 200 No Tumor 
.5% w AOM (IL10) 200 No Tumor 
.5%w PBS (IL10) 200 No Tumor 
.5%w PBS (IL10) 
spontaneous tumor 200 
Some 
Tumor 
 
Figure 2.6: beta-catenin localization in colonic tissue.  Immunohistochemistry (IHC) of a rabbit monoclonal antibody to Beta 
Catenin clone E247 (AbCam) was performed using human colon cancer tissues used as the positive tissue controls. Tissue 
sections were stained with a Discovery XT Automated Immunostainer (Ventana Medical Systems, Inc., Tucson, AZ; VMSI).  
AOM-treated Il10-/- mice and wildtype mice had tumors with increased staining intensity for beta-catenin and localization to the 
membrane, nucleus and cytoplasm (6A).  AOM-treated Il10-/- mice and wildtype mice + 0.5% have normal colon morphology 
and beta-catenin localized primarily to the membrane, as did all PBS-treated mice (6B) with the exception of the one PBS-treated 
Il-10-/- mouse + 0.5% curcumin diet, which had a spontaneous tumor and beta-catenin localized the membrane (6C). 
Table 2.3: beta-catenin IHC Histological scoring.  Immunohistochemistry (IHC) of a rabbit monoclonal antibody to Beta 
Catenin clone E247 (AbCam) was performed using human colon cancer tissues used as the positive tissue controls. Tissue 
sections were stained with a Discovery XT Automated Immunostainer (Ventana Medical Systems, Inc., Tucson, AZ; VMSI).  
Scoring (long scores) was done by a pathologist with a specialty in GI cancers who was blinded to the experimental groups.  300 
is the maximum score, representing the most severe disease phenotype and a score of 100 was the lowest score for this set of 
samples, representing a healthy individual.   
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7.  Curcumin’s role in reducing tumorigenesis is independent of anti-inflammatory 
functions  
 
 Because of curcumin’s well-documented role as an anti-inflammatory agent, we next 
assessed that function in this mouse model system, where it is administered to individuals who 
already have established inflammation.  While the expression of mRNA that transcribes pro-
inflammatory cytokines is generally higher in Il10
-/-
 mice than in wildtype mice, we do not see a 
statistically significant overall trend in curcumin doses to reduce the expression compared to the 
mice on the 0% curcumin control diet (Fig. 2.7).  Of all the doses, the 0.1% curcumin diet is the 
most effective at reducing inflammation, as shown in AOM-treated wildtype mice (for TNF-α, 
proximal and distal regions; IFN , proximal region), AOM-treated Il10
-/-
 mice (IL-1ß, distal 
region) and PBS-treated wildtype mice (IL-17, proximal region).  This corresponds with 
published studies from our lab, where we previously showed that colon morphology was 
improved and pro-inflammatory cytokine production inhibited only at the 0.1% curcumin dose 
when testing a range from 0.1% to 1%.  For that study, curcumin was used as a preventative 
agent in germ-free Il10
-/-
 mice and germ-free Il10
-/-
 mice given microbiota from mice housed in a 
non germ-free, specific-pathogen free facility (Larmonier et al., 2008).  However, the data thus 
far has shown the 0.5% dose to be the most effective for tumor reduction.  This indicates, that 
curcumin’s ability to reduce tumorigenesis is independent of its ability to reduce inflammation 
and that both functions are, respectively, dose-dependent. 
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Figure 2.7: mRNA expression of colitis-associated cytokines within colonic tissue.  Relative quantification of mRNA 
expression of TNF-α, IFNγ, IL-6, IL-1ß and IL17 are shown as a change in expression of the target gene relative to untreated WT 
on control diet.  Each sample was normalized to GAPDH expression.  Bars represent means and SEM.  Groups were considered 
statistically different by a p value < 0.05 using the Student’s t-test (Excel software) to assess in pairs the 2^-ΔΔCt scores of the 
0% diet to each diet concentration within a group.  Exact p values for the statistically significant values are as follows.  Proximal 
TNF-α: WT(AOM) 0% to 0.1%, p = 0.0107.  Distal TNF-α: WT(AOM) 0% to 0.1%, p = 0.0101; 0% to 0.5%, p = 0.0061.  Il10-/-
(AOM) 0% to 0.1%, p = 0.0111.  Proximal IFNγ: WT(AOM) 0% to 0.1%, p = 0.0421.  Proximal IL-1β Il10-/-(PBS) 0% to 0.05%, 
p = 0.0448.  Distal IL-1β Il10-/-(AOM) 0% to 0.1%, p = 0.0067.  Proximal IL-17 WT(PBS) 0% to 0.1%, p = 0.0480; 0% to 0.5%, 
p = 0.0473 and Il10-/-(AOM) 0% to 0.5%, p = 0.0281. 
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8.  Baseline Gut Microbial Composition Patterns between WT and Il10
-/-
 mice 
 Because the anti-cancer effect of curcumin does not mechanistically function through the 
well-described anti-inflammatory role in this model system, we wanted to explore other possible 
targets of curcumin.  Gut microbiota can be affected by diet and contribute to human health in a 
variety of ways, including providing essential and non-redundant functions, such as fermentation 
of otherwise non-digestible dietary components and maintaining homeostasis of the human 
metabolism and immune system (Zhu et al., 2011 and Flint et al., 2012).  We designed an 
experiment to determine whether or not curcumin given in the diet affects the luminal microbial 
composition during the course of disease and treatment.  In order to assess those changes, we 
first determined whether there are any inherent differences in the microbial composition between 
WT and Il10
-/-
 mice and, indeed, we do see a difference in microbial composition patterns (Fig. 
2.8).  Previous work by Arthur et al., 2012, has shown this finding, which provides a verification 
of our microbial diversity analysis and model system, as well as a baseline to determine effects 
of curcumin.  I am extending this work to include a detailed analysis of the microbial 
composition profiles in relation to curcumin supplementation in the diet.  
Alpha diversity is a measure of how many (observed species, OS) and how many 
different types (Phylogenetic Diversity, PD) of bacteria are present in one group of samples.  The 
type of bacteria present are determined from unique variations in the genetic sequence of an 
ecologically conserved gene, 16S rRNA (amplified from bacterial DNA extracted from stool 
samples).  Those unique sequences (in reality, sets of highly similar sequences to take into 
account possible misreads), are assigned to Operational Taxonomic Units (OTU) and each OTU 
is associated with a specific bacteria.  Here, we show that PD varies between WT and Il10
-/-
 mice 
with the richness being greater in the WT mice, as indicated by the higher mean value (Fig. 
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2.8A).  Although not shown on the graph, the OS values do correspond with these findings (p < 
0.05, mean WT: 707.2; mean Il10
-/-
 mice: 542.1).   
Beta diversity, which takes into account similarities of microbial composition among 
groups of samples, also demonstrates a difference in microbial diversity between WT and Il10
-/-
 
mice, as indicated by the separation pattern in the principal coordinate of analysis (pcoa) plot and 
the associated Analysis of Similarity (ANOSIM) (Fig. 2.8B).  Instead of OTU comparisons, beta 
diversity calculations compare distances (unweighted UniFrac distance) along a reference 
phylogenetic tree of microbiota between groups of samples. 
 We next wanted to determine which bacteria, specifically, are different between the WT 
and Il10
-/-
 mice.  Taxa bar charts allow for a quick visual overview of patterns to identify if there 
are differences among groups, as indicated by the colored blocks present (each block represents a 
different microbial taxa) and the size of those blocks in the chart (size corresponds to 
abundance).  Here we show that there are differences between WT and Il10
-/-
 mice in taxonomic 
patterns at the Phyla level and the genera level (Fig. 2.8C).  Specific changes are described 
below (Table 2.4). Microbial taxa that were significantly different between WT and Il10
-/-
 mice 
were primarily in the Bacteroidetes and Firmicutes phyla, which comprise over 90% of the total 
phyla (2.8C).  However, the Il10
-/-
 mice also had an increase in the Bifidobacterium genus within 
the Actinobacteria phyla and a decrease, compared to WT, of two members of the Clostridia 
class, one from the Lachnospiraceae genus and one from an unknown genus.  Some microbial 
taxa, such as the S24-7 genus of the Bacteroidetes phyla were found to sometimes increase in 
Il10
-/-
 mice compared to WT and sometimes decrease, although the same taxonomic hierarchy is 
listed.  This indicates that there are differences at deeper levels than we are currently able to 
detect for that genus, e.g. at the species level.    
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Predicted bacterial metabolic changes associated with the microbial composition pattern 
were generated using PICRUSt (phylogenetic investigation of communities by reconstruction of 
unobserved states) (Langille et al., 2013) are described below (Table 2.5).  Functionally, the 
microbial composition profiles indicate that Il10
-/-
 mice, compared to WT, are predicted to have 
increases in the following pathways: general metabolism category, carbohydrate metabolism in 
particular and the phosphotransferase system (PTS).  Parallel increase in the carbohydrate 
metabolism is logical, as the PTS allows for carbohydrate transport into the bacterial cells.  PTS 
also has a role in biofilm formation and is necessary for initial colonization in germ free animals, 
as well as abiotic surfaces in the environment (Houot et al., 2010).  The Il10
-/-
 mice have 
predicted decreases in the following pathways: cell motility, membrane transport, flagellar 
assembly, bacterial motility and the general transporter category.   
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Figure 2.8:  Microbial diversity analysis of WT and Il10-/- mice 
Alpha diversity was calculated as phylogenetic diversity using the QIIME software, which utilizes a non-parametric t-test.  The 
p-value = 0.003 (8A).  Beta diversity pcoa plots were generated in QIIME and analyzed using Analysis of Similarity.  The p-
value = 0.001 (8B).  The taxonomic grouping bar chart was also generated in QIIME and modified to include % abundance and 
labels in Microsoft Powerpoint (8C)
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Differences in microbial composition of Il10
-/-
 compared to WT    
OTU 
mean 
WT 
mean 
Il10
-/-
 Pattern Phyla Class Order Family 
Genus/ 
Species 
559527 0.0040 0.0125 higher Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae 
Bifidobact-
erium 
535375 0.0309 0.1214 higher Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae B. ovatus 
291090 0.0016 0.0106 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. distasonis 
585914 0.0010 0.0069 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. distasonis 
276149 0.0036 0.0096 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. gordonii 
384555 0.0056 0.0110 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
348038 0.0244 0.0507 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
356760 0.0001 0.0112 higher Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae   
3013444 0.0322 0.0107 lower Bacteroidetes Bacteroidia Bacteroidales     
162539 0.0073 0.0011 lower Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae   
276802 0.0076 0.0020 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
196645 0.0064 0.0011 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
272850 0.0366 0.0146 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
331043 0.0148 0.0077 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
372368 0.0068 0.0042 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
199532 0.0089 0.0017 lower Firmicutes Clostridia Clostridiales     
1105981 0.0079 0.0018 lower Firmicutes Clostridia Clostridiales Lachnospiraceae   
 
 
Table 2.4: Specific changes in microbial composition of Il10-/- mice compared to WT 
This is a summary of changes in microbial composition generated using the QIIME software, which utilizes the Bonferroni-corrected method of multivariate analysis.  OTUs and 
their associated bacteria taxa were considered “different” if the p-value < 0.05. Comparison of the means determined the abundance trend pattern.  All p-values = 0.0000, except 
OTU#559527 where the p-value = 0.0002. 
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Predicted Pathway - overall mean WT mean Il10
-/-
 Pattern 
Metabolism 0.4754 0.4851 higher 
Cellular Processes 0.0336 0.0255 lower 
Environmental Information Processing 0.1405 0.1328 lower 
Predicted Pathway - type    
Carbohydrate Metabolism 0.1085 0.1129 higher 
Cell Motility 0.0242 0.0159 lower 
Membrane Transport 0.1229 0.1168 lower 
Predicted Pathway - specific    
General function prediction only 0.0345 0.0358 higher 
Phosphotransferase system (PTS) 0.0045 0.0060 higher 
Flagellar assembly 0.0055 0.0030 lower 
Bacterial motility proteins 0.0103 0.0061 lower 
Transporters 0.0720 0.0664 lower 
 
 
Table 2.5: Predictions of microbial metagenome and function based on microbial composition of Il10-/- mice and WT mice 
Predictions of pathways were generated by the PICRUSt software, which uses the 16S rRNA sequences present in a sample and an ancestral-state reconstruction algorithm to 
predict gene families and estimate the composite metagenome.  PICRUSt results were analyzed using QIIME.  This table represents statistically significant differences as 
calculated by the Bonferroni-corrected multivariate analysis in predicted pathways associated with abundance(s) of OTUs.  Differences were considered significant if the p < 0.05.  
All p-values = 0.0000. 
  
6
7
 
68 
 
9. Microbial analysis of the effect of curcumin-supplemented diet 
Because of the striking reduction of tumor burden in mice receiving the 0.5% curcumin 
diet, we wanted to further investigate whether this effect was associated with a change in 
microbial diversity (Fig. 2.9).  We observed a separation in the clustering pattern in the beta 
diversity principal coordinate of analysis (pcoa) plots by the Diet-Gene-Treatment groups which 
was maintained over the course of the study (2.9A).  Indeed, the taxonomic profiling of mice 
receiving the 0.5% diet vs. the 0% control diet showed a different microbial composition pattern 
as shown visually by the taxonomic bar charts (2.9B).  Although the profiles did visually vary 
between the Il10
-/-
 (PBS and AOM groups) mice on the start date of the study, these were not 
statistically significant and, for clarity of purposes, only the PBS-injected Il10
-/-
 mouse group is 
shown in the taxa bar chart representing week 0 samples from that genotype. 
Because our hypothesis was that curcumin would modulate the microbial ecology of 
AOM-treated chronically-inflamed Il10
-/- 
mice to become similar in composition to that of 
healthy, untreated wildtype mice, thus restoring the gut homeostasis of those mice, we next 
compared the microbial composition profiles of the AOM-injected Il10
-/-
 mice on the control diet 
(0%) to the untreated WT mice on control diet (Table 2.6) and the AOM-injected Il10
-/-
 mice on 
the 0.5% curcumin diet to the untreated WT mice on the control diet (Table 2.6).  Of the OTUs 
that are significantly different from WT mice, thirteen are shared among the Il10
-/-
 mice (OTU# 
276149, 384555, 535375, 214919, 352049, 262095, 359809, 196645, 272850, 1107027, 337494, 
588197 and 592160). 11 of these OTUs have the same trend (higher or lower) compared to the 
healthy WT mice and only 2 have different trends based on diet.  These two OTUs (588197 and 
592160) are both in the Firmicutes phyla and Lactobacillus genus.  Both of these OTUs are 
lower in the AOM-injected Il10
-/-
 mice on the control diet (0% curcumin) and higher in the 
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AOM-injected Il10
-/-
 mice on the 0.5% curcumin diet.  This is intriguing because the AOM-
treated Il10
-/-
 mice on the 0.5% had such a striking improvement in reduction of tumors and the 
Lactobacillus genus is associated with cell cycle arrest and induction of apoptosis in colon cancer 
cell lines (Wan et al., 2014 and Wang et al., 2014).  While the Clostridium genus stands out on 
the taxa charts, it failed to reach significance by Bonferroni-corrected multivariate analysis or 
nonparametric t-tests (p-value = 0.2548) for the groups of interest, most likely due to the 
variation of its abundance within the individual Il10
-/-
 mice. 
Statistically significant differences in microbial composition OTUs unique to the AOM-
injected Il10
-/-
 mice on the control diet, or AOM-injected Il10
-/-
 mice on the 0.5% curcumin diet, 
respectively, compared to healthy untreated WT are reported (Table 2.7 and Table 2.8).  As with 
the Il10
-/-
 mice on the control diet, the Il10
-/-
 mice given 0.5% curcumin diets showed changes, 
compared to untreated WT control mice, primarily in the Bacteroidetes and Firmicutes phyla, 
although Il10
-/-
 mice given 0.5% curcumin diet also had an increase in Bifidobacterium from the 
Actinobacteria phylum.  Bifidobacteria are associated with a healthy state in the colon, are used 
in probiotics and have been shown to reduce aberrant crypt foci in mice receiving a chemical 
carcinogen, dimethylhyrazine (Liboredo et al., 2013).  Bifidobacteria, along with Lactobacillus 
genus (Bacteroidetes phyla) and Sutterella genus (Proteobacteria phyla) also produce esterases, 
which can liberate ester-linked nutrient sources that the human host would otherwise be unable 
to utilize (Mukhopadhya et al., 2011).  Sutterella is also increased in Il10
-/-
 mice given the 0.5% 
curcumin diet.  Lactobacillus and S24-7 is found to both increase and decrease, which indicates 
that there are differences in those OTUs at deeper levels, such as species, that we are currently 
unable to detect.   
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The predicted function pathways based on these microbial composition profiles are 
reported (Table 2.9).  The “healthier” Il10-/- mice receiving the 0.5% curcumin diet that had the 
reduction in tumor burden compared to the Il10
-/-
 mice on the control (0% curcumin) diet, had 
decreases in the following: general cellular processes, environmental processing, cell motility, 
transcription, membrane transport, 2-component system, transcription factors and transporters.  
They had increases in the following pathways: general metabolism, genetic information 
processing, translation, oxidation phosphorylation, aminoacyl-tRNA biosynthesis, purine 
metabolism, pyrimidine metabolism and DNA repair and recombination proteins.  The Il10
-/-
 
mice on the control diet have, by comparison, a decrease in DNA repair mechanisms, which may 
contribute to the increased risk for colon cancer onset, as well as a decrease in metabolism 
pathways, which may make that group more prone to microbial nutrient deficiencies. 
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Figure 2.9:  Microbial diversity analysis of WT and Il10-/- mice 
Beta diversity pcoa plots were generated in Qiime and analyzed using Analysis of Similarity (9A).  The p-value was 0.0010 and 
the R-value = 0.5156.  The taxonomic grouping bar chart was also generated in Qiime and modified to include % abundance and 
labels in Microsoft Powerpoint (9B) 
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Abundance of OTUs of AOM-Il10
-/-
 + 0% curcumin compared to PBS-WT + 0% curcumin (week 20)  
OTU 
mean 
(WT) 
mean    
(Il10
-/-
) Pattern Phyla Class Order Family Genus/ species 
535375 0.0147 0.0995 higher Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae B. ovatus 
291090 0.0014 0.0120 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonada-ceae P. distasonis 
276149 0.0015 0.0144 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonada-ceae P. gordonii 
384555 0.0028 0.0208 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
214919 0.0009 0.0157 higher Firmicutes Bacilli Turicibacterales Turicibacteraceae Turicibacter 
352049 0.0000 0.0283 higher Firmicutes Clostridia Clostridiales     
262095 0.0000 0.0126 higher Firmicutes 
Erysipelot-
richi Erysipelotrichales Erysipelotrichace-ae   
359809 0.0013 0.0134 higher Proteobacteria 
Betaproteoba
cteria Burkholderiales Alcaligenaceae Sutterella 
272850 0.0406 0.0025 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
196645 0.0115 0.0000 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
356226 0.0254 0.0129 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
1107027 0.3083 0.1476 lower Firmicutes Bacilli Lactobacillaceae Lactobacillaceae Lactobacillus 
592160 0.0130 0.0085 lower Firmicutes Bacilli Lactobacillaceae Lactobacillaceae Lactobacillus 
588197 0.0120 0.0087 lower Firmicutes Bacilli Lactobacillaceae Lactobacillaceae L. reuteri 
337494 0.0475 0.0007 lower Firmicutes Clostridia Clostridiales     
 
Table 2.6:  microbial composition profile of the AOM-injected Il10
-/-
 mice on the control diet (0%) compared to the untreated WT mice on control diet.  
This is a summary of changes in microbial composition generated using the QIIME software, which utilizes the Bonferroni-corrected method of multivariate analysis.  OTUs and 
their associated bacteria taxa were considered “different” if the p-value < 0.05. Comparison of the means determined the abundance trend pattern.  All p-values were 0.0000, 
except OTU# 352049 (p = 0.0001) and OTU# 588197 (p = 0.0010).    
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Abundance of OTUs between AOM-Il10
-/-
 + 0.5% curcumin and PBS-WT + 0% curcumin (week 20)  
OTU 
mean 
(WT) 
mean    
(Il10
-/-
) Pattern Phyla Class Order Family Genus/ Species 
559527 0.0008 0.0349 higher Actinobacteria 
Actinobac-
teria Bifidobacteriales Bifidobacteriaceae Bifidobacteri-um 
3013444 0.0063 0.0180 higher Bacteroidetes Bacteroidia Bacteroidales     
535375 0.0147 0.0800 higher Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae B. ovatus 
276149 0.0015 0.0104 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. gordonii 
271131 0.0025 0.0162 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
175706 0.0000 0.0140 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
384555 0.0028 0.0118 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
337724 0.0034 0.0119 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
592160 0.0130 0.0871 higher Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
588197 0.0120 0.0219 higher Firmicutes Bacilli Lactobacillales Lactobacillaceae L. reuteri 
214919 0.0009 0.0175 higher Firmicutes Bacilli Turicibacterales Turicibacteraceae Turicibacter 
352049 0.0000 0.0118 higher Firmicutes Clostridia Clostridiales     
276478 0.0007 0.0116 higher Firmicutes Clostridia Clostridiales Peptostreptococcaceae   
262095 0.0000 0.0238 higher Firmicutes 
Erysipelot-
richi Erysipelotrichales Erysipelotrichaceae   
356760 0.0001 0.0278 higher Firmicutes 
Erysipelot-
richi Erysipelotrichales Erysipelotrichaceae   
180869 0.0028 0.0236 higher Firmicutes 
Erysipelot-
richi Erysipelotrichales Erysipelotrichaceae   
4407703 0.0000 0.0129 higher Firmicutes 
Erysipelot-
richi Erysipelotrichales Erysipelotrichaceae Coprobacillus 
359809 0.0013 0.0226 higher Proteobacteria 
Betaprote-
obacteria Burkholderiales Alcaligenaceae Sutterella 
272850 0.0406 0.0110 lower Bacteroidetes Bacteroidia Bacteroidales     
276802 0.0103 0.0043 lower Bacteroidetes Bacteroidia Bacteroidales     
196645 0.0115 0.0013 lower Bacteroidetes Bacteroidia Bacteroidales     
261350 0.0188 0.0039 lower Bacteroidetes Bacteroidia Bacteroidales     
348038 0.0698 0.0335 lower Bacteroidetes Bacteroidia Bacteroidales     
1107027 0.3083 0.1014 lower Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
337494 0.0475 0.0000 lower Firmicutes Clostridia Clostridiales     
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Table 2.7:  microbial composition profile of the AOM-injected Il10
-/-
 mice on the 0.5% curcumin diet compared to the untreated WT mice on the 
control diet.  This is a summary of changes in microbial composition generated using the QIIME software, which utilizes the Bonferroni-corrected method of multivariate 
analysis.  OTUs and their associated bacteria taxa were considered “different” if the p-value < 0.05. Comparison of the means determined the abundance trend pattern.  All p-
values = 0.0000, except OTU# 337724 (p = 0.0003), OTU# 588197 (p = 0.0010) and OTU# 352049 (p = 0.0001). 
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Microbial composition patterns unique to 0% AOM-Il10
-/-
 compared to 0% PBS-WT  
OTU 
mean 
(WT) 
mean        
(Il10-
/-) Pattern Phyla Class Order Family Genus/ species 
291090 0.0014 0.0120 higher Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. distasonis 
356226 0.0254 0.0129 lower Bacteroidetes Bacteroidia Bacteroidales S24-7   
         
Microbial composition patterns unique to 0.5% AOM-Il10
-/- 
 compared to 0% PBS-WT  
OTU 
mean 
(WT) 
mean        
(Il10-
/-) Pattern Phyla Class Order Family Genus/ species 
559527 0.0008 0.0349 higher Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium 
175706 0.0000 0.0140 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
271131 0.0025 0.0162 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
337724 0.0034 0.0119 higher Bacteroidetes Bacteroidia Bacteroidales S24-7   
3013444 0.0063 0.0180 higher Bacteroidetes Bacteroidia Bacteroidales     
276478 0.0007 0.0116 higher Firmicutes Clostridia Clostridiales Peptostreptococcaceae   
180869 0.0028 0.0236 higher Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae   
356760 0.0001 0.0278 higher Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae   
4407703 0.0000 0.0129 higher Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Coprobacillus 
261350 0.0188 0.0039 lower Bacteroidetes Bacteroidia Bacteroidales     
276802 0.0103 0.0043 lower Bacteroidetes Bacteroidia Bacteroidales     
348038 0.0698 0.0335 lower Bacteroidetes Bacteroidia Bacteroidales     
 
Table 2.8:  microbial composition profiles of the AOM-injected Il10-/- mice on their respective diets, 0% or 0.5% compared to the untreated WT mice on the control diet.  
This is a summary of changes in microbial composition generated using the QIIME software, which utilizes the Bonferroni-corrected method of multivariate analysis.  OTUs and 
their associated bacteria taxa were considered “different” if the p-value < 0.05. Comparison of the means determined the abundance trend pattern.  All p-values = 0.0000, except 
OTU# 337724 (p = 0.0003). 
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Predicted pathway - overall 
mean 
PBS-WT                    
0%  
mean 
AOM-Il10
-
/-
         0% 
Pattern 
____ than 
WT 
mean 
AOM-
Il10
-/-
 
0.5% 
Pattern 
____ than 
WT  
mean 
AOM-
Il10
-/-
         
0% 
mean 
AOM-
Il10
-/-
 
0.5% 
Trend ____ 
than AOM-
Il10-/- 0% 
Unclassified 0.1329 0.1403 higher 0.1383 higher  0.1403 0.1383 lower 
Cellular Processes 0.0333 0.0301 lower 0.0243 lower  0.0301 0.0243 lower 
Metabolism 0.4773 0.4711 lower 0.4843 higher  0.4711 0.4843 higher 
Genetic Information Processing 0.1999 0.1979 lower 0.2058 higher  0.1979 0.2058 higher 
Environmental Information 
Processing 0.1418 0.1452 higher 0.1313 lower  0.1452 0.1313 lower 
Predicted pathway - type                  
Cellular Processes and Signaling 0.0353 0.0402 higher 0.0387 n.s.  0.0402 0.0387 n.s. 
Cell Motility 0.0236 0.0213 n.s. 0.0146 lower  0.0213 0.0146 lower 
Transcription 0.0269 0.0299 n.s. 0.0263 n.s.  0.0299 0.0263 lower 
Glycan Biosynthesis and Metabolism 0.0276 0.0233 lower 0.0270 n.s.  0.0233 0.0270 n.s. 
Membrane Transport 0.1245 0.1282 n.s. 0.1151 lower  0.1282 0.1151 lower 
Translation 0.0579 0.0553 n.s. 0.0610 higher  0.0553 0.0610 higher 
Predicted pathway - specific                  
Other ion-coupled transporters 0.0116 0.0126 higher 0.0129 higher  0.0126 0.0129 n.s. 
General function prediction only 0.0337 0.0361 higher 0.0358 higher  0.0361 0.0358 n.s. 
Two-component system 0.0141 0.0136 n.s. 0.0125 lower  0.0136 0.0125 lower 
Purine metabolism 0.0236 0.0223 lower 0.0232 n.s.  0.0223 0.0232 higher 
Oxidative phosphorylation 0.0112 0.0106 n.s. 0.0121 higher  0.0106 0.0121 higher 
Aminoacyl-tRNA biosynthesis 0.0123 0.0115 n.s. 0.0125 n.s.  0.0115 0.0125 higher 
Transcription factors 0.0163 0.0184 higher 0.0148 lower  0.0184 0.0148 lower 
DNA repair and recombination 
proteins 0.0289 0.0282 lower 0.0297 higher  0.0282 0.0297 higher 
Transporters 0.0737 0.0727 lower 0.0642 lower  0.0727 0.0642 lower 
Pyrimidine metabolism 0.0197 0.0188 lower 0.0196 n.s.  0.0188 0.0196 higher 
 
Table 2.9:  Predicted pathways based on microbial composition profiles of the AOM-injected Il10-/- mice on their respective diets, 0% or 0.5% compared to the 
untreated WT mice on the control diet.  Predictions of pathways were generated by the PICRUSt software, which uses the 16S rRNA sequences present in a sample and an 
ancestral-state reconstruction algorithm to predict gene families and estimate the composite metagenome.  PICRUSt results were analyzd using QIIME.  This table represents 
statistically significant differences as calculated by the Bonferroni-corrected multivariate analysis in predicted pathways associated with abundance(s) of OTUs.  Differences were 
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considered significant if the p > 0.05.  All p-values = 0.0000, except Genetic Information Processing (p = 0.0003), Environmental Information Processing (p = 0.0017), 
Aminoacyl-tRNA biosynthesis (p = 0.0006), Transcription factors (p = 0.0051) and Pyrimidine metabolism (p = 0.0384). 
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10. Microbial composition patterns associated with colon cancer induction 
We next wanted to further explore the association of microbial composition profiles in 
relation to carcinogenesis in the colon (Fig. 2.10).  We found that there is a statistically 
significant difference in the microbial composition profiles between mice without tumors and 
mice with tumors (2.10A-B).  Furthermore, there are differences in microbial composition when 
we differentiate samples based on spontaneity or chemical induction (2.10C-D).  The majority of 
mice with tumors are Il10
-/-
 mice (as described in Fig. 2.5).  Separation can not be based 
primarily on genotype because they would all cluster together.  Instead, the clustering pattern is 
associated with presence of tumor and what type of tumor induction.  Taxa bar charts allow for a 
quick visual overview in patterns to see if there are differences among groups, defined as mice 
without tumors vs. mice with tumors (2.10E) and PBS-injected mice with spontaneous tumors 
versus AOM-injected mice with tumors (2.10F).  It is important to note that all microbial DNA 
samples from tumor-bearing mice in the AOM-injected groups were treated as “induced.”  
Specific changes in microbial composition are reported (Table 2.10).  There are relatively few 
differences in abundance of OTUs between samples with tumor and samples without.  The 
microbial composition profile from samples with spontaneous tumors and from samples with 
induced tumors both have an increase in B. ovatus compared to samples from mice without 
tumors.  However, they differ in all other identified OTUs compared to samples without tumor.  
The microbial composition profile of the samples from mice with spontaneous tumors have a 
higher abundance of OTUs within the Bacteroidetes phyla, compared to samples from mice 
without tumors.  The microbial composition profile of the samples from mice with induced 
tumors have higher abundance of OTUs within the Firmicutes phyla, compared to samples from 
mice without tumors.  This same pattern is maintained when the groups of samples from mice 
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with tumors are compared to each other.  The induced tumor samples have higher abundance in 
Firmicutes than the spontaneous tumor samples.   
The predicted pathways associated with these microbial composition profiles are reported 
in Table 2.11.  The predicted pathways based on the microbial composition are the same for both 
groups of samples from mice with spontaneous or induced tumors, respectively.  However, the 
predicted function of those pathways is opposite.  In comparison to samples from mice with no 
tumors, microbiota within mice that have spontaneous tumors are predicted to have a decrease in 
environmental processing, membrane transport and transporters, while having an increase in 
general metabolism pathways.  The opposite is predicted for the microbiota within mice that 
have induced tumors, compared to mice with no tumors.  When the groups are compared to each 
other, microbiota from mice with induced tumors are predicted to have pathways less active for 
metabolism, but more active for environmental processing, membrane transport and transporters. 
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Figure 2.10: Microbial composition patterns associated with colon cancer induction 
Alpha diversity was calculated as phylogenetic diversity using the QIIME software, which utilizes a non-parametric t-test (10A, 
10C).  The alpha diversity p-value for samples from mice with tumors vs. mice without tumors was 0.0060.  The alpha diversity 
p-value for samples from mice with spontaneous tumors vs. from mice with induced tumors was 0.024.  Beta diversity pcoa plots 
were generated in QIIME and analyzed using Analysis of Similarity (10B, 10D).  The p-value for the ANOSIM analysis for 
samples from mice with tumors vs. mice without tumors was 0.001 and the R-value was 0.3797.  The p-value for the ANOSIM 
analysis for samples from mice with spontaneous tumors vs. from mice with induced tumors was 0.001 and the R-value was 
0.3821).  The taxonomic grouping bar chart was also generated in QIIME and modified to include % abundance and labels in 
Microsoft Powerpoint for mice with no tumor and mice with tumors (10E), as well as for mice with spontaneous vs. AOM-
induced tumors (10F). 
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A         
Microbial composition patterns of spontaneous tumors samples compared to samples without tumor 
OTU 
mean 
none 
mean 
spon. Pattern Phyla Class Order Family Genus/ Species 
343853 0.0012 0.0057 higher Bacteroidetes Bacteroidia Bacteroidles S24-7   
589277 0.0014 0.0093 higher Bacteroidetes Bacteroidia Bacteroidles Bacteroidaceae Bacteroides 
535375 0.0712 0.1796 higher Bacteroidetes Bacteroidia Bacteroidles Bacteroidaceae B. ovatus 
291090 0.0056 0.0154 higher Bacteroidetes Bacteroidia Bacteroidles Porphyromonadaceae P. distasonis 
         
         
B         
Microbial composition patterns of induced tumors samples compared to samples without tumor 
OTU 
mean 
none 
mean 
induced 
Patter
n Phyla Class Order Family Genus/ Species 
535375 0.0712 0.0728 higher Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae B. ovatus 
337494 0.0040 0.0226 higher Firmicutes Clostridia Clostridiales     
277143 0.0017 0.0225 higher Firmicutes Erysipelotrichales 
Eysipelotric-
hales Erysipelotrichaceae Allobaculum 
         
         
C         
microbial composition patterns of samples from mice with induced tumors compared to spontaneous tumors 
OTU 
mean 
spon. 
mean 
induced Pattern Phyla Class Order Family 
Genus/ 
Species 
589277 0.0093 0.0002 lower Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
535375 0.1796 0.0728 lower Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
585914 0.0101 0.0046 lower Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. distansonis 
291090 0.0154 0.0069 lower Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae P. distansonis 
337494 0.0000 0.0226 higher Firmicutes Clostridia Clostridiales     
277143 0.0001 0.0225 higher Firmicutes Erysipelotric-hi Erysipelotricha-les Eryipelotrichaceae Allobacul-um 
 
Table 2.10: Microbial Composition Profiles of samples from mice with spontaneous tumors, induced tumors and no tumors. 
This is a summary of changes in microbial composition generated using the QIIME software, which utilizes the Bonferroni-corrected method of multivariate analysis.  OTUs and 
their associated bacteria taxa were considered “different” if the p-value < 0.05. Comparison of the means determined the abundance trend pattern.  The p-values = 0.0000, except 
OTU# 291090 (p = 0.0167), OTU# 337494 (p = 0.0062) and OTU# 585914 (p = 0.0136).  
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Predicted pathway - 
overall 
mean        
none 
mean 
spontaneous 
Pattern 
__ than 
none 
mean 
induced 
Pattern   
__ than 
none  
mean 
spontaneous 
mean 
induced 
Pattern __ 
than 
spontaneous 
Unclassified 0.1366 0.1413 higher 0.1370 n.s.  0.1413 0.1370 lower 
Environmental Information 
Processing 0.1370 0.1296 lower 0.1381 higher  0.1296 0.1381 higher 
Metabolism 0.4797 0.4911 higher 0.4838 lower  0.4911 0.4838 lower 
Predicted pathway - type                  
Membrane Transport 0.1200 0.1143 lower 0.1220 higher  0.1143 0.1220 higher 
Predicted pathway - 
specific                  
Transporters 0.0694 0.0659 lower 0.0708 higher  0.0659 0.0708 higher 
 
Table 2.11: Predictions of pathways in mice (spontaneous tumors vs induced tumors) based on microbial composition profiles 
Predictions of pathways were generated by the PICRUSt software, which uses the 16S rRNA sequences present in a sample and an ancestral-state reconstruction algorithm to 
predict gene families and estimate the composite metagenome.  PICRUSt results were analyzed using QIIME.  This table represents statistically significant differences as 
calculated by the Bonferroni-corrected multivariate analysis in predicted pathways associated with abundance(s) of OTUs.  Differences were considered significant if the p > 0.05.  
The p-values were as follows: Unclassified (p = 0.0000), Environmental Information Processing (p = 0.0131), Metabolism (p = 0.0300), Membrane Transport (p = 0.0155) and 
Transporters (p = 0.0251). 
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CHAPTER 3: DISCUSSION 
 
A. Effects of microbiota on progression and incidence of colon cancer 
 
Review and verification of mouse model of CAC 
Using a colitis-associated colon cancer mouse model system, Il10
-/-
 mice and the wildtype 
control mice were allowed to age to 10 weeks by which point the Il10
-/-
 mice develop a 
spontaneous and progressive colitis (Kühn et al., 1993 and Gomes-Santos et al., 2012).  We fed 
the wildtype and the chronically inflamed Il10
-/-
 mice with curcumin in their pelleted diets at the 
following doses: 0% (control diet), 0.05%, 0.1%, 0.5% and 1%.  These mice were injected with 
either a carcinogen, azoxymethane (AOM), or a placebo, Phosphate Buffered Saline (PBS) once 
per week for six weeks total (Figure 2.1).  We were able to induce tumors through the use of 
AOM and tumor burden was increased for Il10
-/-
 mice receiving AOM, compared to WT mice 
receiving AOM and compared to Il10
-/-
 mice that did not receive AOM (Figure 2.5). 
 
1. How this data fits in with current research in the field 
This research adds to the field by describing differences in microbial populations based 
on induction of tumors, whether in mice exposed to AOM, or in mice with no AOM exposure 
(spontaneous).  The microbial composition profile differs by tumor induction, whether 
spontaneous or AOM-induced, among mice that have tumors compared to mice that did not 
develop tumors.  Of the bacteria found to statistically differ from those within mice with no
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 tumors, the Bacteroidetes phyla dominate the microbial composition profile of mice with 
spontaneous tumors, while Firmicutes dominate the microbial composition profile of mice with 
AOM-induced tumors (Table 2.10).   
Because Bifidobacteria and Lactobacilli were found to be statistically different among 
curcumin treated vs. control diet groups, we wanted to compare abundance of Bifidobacteria and 
Lactobacilli between mice with tumor vs. no tumor or between mice with spontaneous vs. AOM-
induced tumors.  However, differences in these were not found to be statistically significant in 
the context of cancer.  It is interesting to note that previous studies have seen a correlation of 
increased abundance of Lactobacillus in patients with low risk for colon cancer, vs. patients at 
high risk for colon cancer.  Risk assessments were based on number of polyps and a history of 
chronic inflammatory bowel diseases (Moore et al., 1995).  I would like to explore this upon 
repeating the studies and increasing the number of mice per group in both spontaneous vs. 
chemically-induced cancer populations. 
We discovered that differences in predicted bacterial pathways, namely bacterial 
transporters, vary based on spontaneous vs. induced tumors, which is novel to the field.  The 
expression of transporters of gut microbiota is predicted to vary by development of spontaneous 
vs. AOM-induced tumors (Table 2.11).  Bacterial transporters were predicted to be lower in 
mice with spontaneous tumors compared to the mice that do not have tumors, while the opposite 
was predicted for bacterial transporters in mice with induced tumors compared to mice without 
tumors.  I would like to extend this finding to explore if certain host transporters associated with 
colon cancer, such as SLC5A8, are decreased in Il10
-/-
 mice, making them higher risk to develop 
colon cancer, or if expression of transporters varies depending on spontaneous or AOM-induced 
colon cancer.  SLC5A8 is a sodium-coupled transporter that not only transports beneficial short 
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chain fatty acids (SCFAs), but also functions as a tumor suppressor that is commonly mutated in 
colon cancer (Ganapathy et al., 2013).   Characterizing changes in transporters may allow for 
better biomarkers for colon cancer, as well as indicate function within the colon epithelium.   
 
2. Future directions of influences of microbiota on colon cancer 
The numbers of mice in this study, though over 100 animals total, resulted in few mice 
per diet/treatment group (n = 6).  Now, that we have a clearer understanding of effective dose on 
reduction of tumor burden, there are many avenues for which to explore. 
 
 Evaluate effects of curcumin to reduce severity/score of spontaneous vs. induced colon 
cancer in the AOM/Il10
-/-
 mouse model 
A. We would characterize the differences in spontaneous vs. induced colon cancer with and 
without 0.1% curcumin treatment for: a) microbial composition patterns by 16S rRNA 
sequencing and Qiime analysis, b) genetic mutations present by microarray c) gene expression 
and local production within Mesenteric Lymph Nodes of pro-inflammatory 
cytokines/chemokines produced of tumor tissue and adjacent non-tumor tissue, d) 
inflammatory cell infiltration characterization, d) beta-catenin, NF-κB, Ki67 expression by 
IHC. 
B. We would further explore the necessity of microbiota in curcumin’s mechanism of action by 
a) co-housing mice on the same diet with and without the AOM carcinogen to observe any 
changes in tumor burden and characterization of the tumors due to changes in microbial 
composition within a shared environment. 
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 Evaluate curcumin as an effective agent in reducing tumor burden and likelihood of 
progressing to colon cancer from a state of chronic inflammation 
We would repeat the studies, focusing on the 0.5% diet to increase the statistical 
power of the analysis.  We would characterize as above to identify other potential mechanisms 
of action of curcumin in tumor reduction.   
 
 Microbial colonization of tumor tissue during development and progression of colon 
cancer 
The predicted metabolic pathways indicated an increase in PTS for the Il10
-/-
 mice 
compared to WT.  This system is associated with early colonization of bacteria in GF mice, as 
well as on abiotic surfaces (Houot et al., 2010).  This finding suggests a stepwise colonization 
of tumor tissue that is currently poorly understood.  The metabolic needs of bacteria for 
survival in a tumor context may be very different than in a tumor-free epithelium, given that 
the tumor-burdened epithelium may no longer be bringing in nutrients and the mucus layer 
may not be being produced continuously in these regions.  So, the physical environment for 
colonization and the available nutrients may change in the context of cancer.   
The tumor may also be producing anti-inflammatory factors, which could potentially 
shield the bacteria from immune system surveillance in the local environment, which may 
affect which specific bacteria can flourish without that limiting factor.   
It would be intriguing to set up a study to explore microbial colonization of a tumor.  
Endoscopy could allow for detection of tumor development during a mouse study and stool 
samples could be collected throughout the study for analysis of the overall composition.  
Ideally, biopsy samples could be obtained during endoscopy, although this may not be an 
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option, currently for the technology available for mice.  However, tissue samples from the 
tumor and adjacent non-tumor tissue could be collected from mice upon euthanasia where 
some mice are taken for tissues early in the study and some are allowed to develop the colon 
cancer for months and taken for tissue analysis at a later time.  This can be compared to 
human biopsy samples from tumor and adjacent non-tumor tissue.   
We could further compare tissue samples from spontaneous vs. induced tumors in the 
proposed mouse studies above to investigate the effect of curcumin on epithelium barrier 
properties in the context of microbial invasion.  An additional question I would like to answer 
is how microbial biofilm production potentially affects metastasis potential of a colonic 
tumor. 
Other possible mechanisms to explore that were not addressed in this investigation 
include exploring the effect of curcumin on colon cancer metastasis (Radhakrishnan et al., 
2014) and the role of curcumin to inhibit NFκB (Larmonier et al., 2008), which would 
potentially allow cells to be more susceptible to TNF-α-mediated apoptosis. 
 
B.  Curcumin functions as an effective anti-colon cancer agent 
 
1. How this data fits in with current research in the field 
Larmonier, et al. (2008) demonstrated that increasing curcumin does not necessarily 
equate to increasing effectiveness and we have verified those findings.  The toxicity of large 
doses when administered with AOM and given to the chronically inflamed Il10
-/-
 mice indicates 
that dose is an important factor to consider.  Curcumin has been observed to be well tolerated in 
healthy adult humans (Lao et al., 2006).  However, this tolerance to large amounts of curcumin 
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has not been reported in patients with active disease.  This dissertation research adds to the field 
by exploring the appropriate dose of curcumin in chronically inflamed mice.  It also adds to the 
field by suggesting in which patient populations this treatment will be most effective, as it is 
possible that curcumin may be most effective in patient populations where patients with 
polymorphisms in IL10, or the receptor for IL10, are excluded from this treatment strategy.  
Although our original hypothesis tested whether or not curcumin could be used to 
influence microbial composition patterns to shift in inflamed mice closer to that of healthy 
individuals, we did not see a strong effect at any of the doses tested.  However, this is a benefit 
as it could potentially be used concomitantly with other colon cancer treatments without the 
concern of shifting the microbial composition and initiating further inflammatory response 
events.  The gut microbiota appears especially sensitive to dietary environmental factors.  Thus, 
having a treatment option that does not cause dramatic shifts in the microbiota is useful in the 
medicinal field and would also be less invasive and potentially less expensive and facilitate FDA 
approval, as it can be administered as a dietary supplement.  In addition to microbial 
compositional changes, functional analyses of the microbiome using transcriptomics will be 
beneficial. 
Concerning the effects of curcumin on microbial profiles, data indicates a shift towards 
bacteria associated with gut health.  Bifidobacteria is associated with health in the colon 
(Liboredo et al., 2013) and yet it was identified as increased overall in the chronically inflamed 
Il10
-/-
 compared to the wildtype (WT) mice. (Table 2.4), which was unexpected.  However, 
when we investigate the microbial composition of Il10
-/-
 mice in relation to the curcumin diet 
group, we see a pattern emerge.  The Il10
-/-
 mice fed the 0.5% curcumin diet have an increase in 
Bifidobacteria (Table 2.7 and Table 2.8), while the Il10
-/-
 mice on the control (0% curcumin) 
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diet are not statistically different from the healthy WT mice on control diet.  This pattern holds 
true for Lactobacillus, another bacteria which is considered beneficial to the health of the colon.  
Both Bifidobacteria and Lactobacilli are used as probiotics and function to produce esterase’s, 
which can liberate ester-linked nutrient sources that the host would otherwise be unable to utilize 
(Mukhopadhya et al., 2011).  This research adds to the field by indicating that curcumin has an 
advantageous effect to shift the microbial composition towards bacteria that are known to be 
beneficial to the health of the colon. 
 
1.  Metabolism 
The increase in Bacteroidetes in Il10
-/-
 mice, compared to WT, corresponds with an 
increase in carbohydrate metabolism (Table 2.5), which suggests utilization of the 
Bacteroidetes’ carbohydrate fermentation pathway as an energy source in the inflamed mice.  
This further corresponds to an increase in the phosphotransferase system (PTS) pathway, which 
allows for carbohydrate transport into bacterial cells (Table 2.5).  The purine and pyrimidine 
metabolism was decreased compared to WT.  Purines and pyrimidines are critical for DNA 
replication and survival.  The metabolism pathways allow for do novo synthesis, as well as 
harvesting them from nucleic acid turnover or from food, which allows the bacteria flexibility in 
the sources of nucleotides, especially if unable to acquire them from the environment.  Addition 
of curcumin in the diet at a dose of 0.5% resulted in an increase in purine and pyrimidine 
metabolism pathways to be similar to that of healthy WT mice on the control diet (Table 2.9), 
which suggests a beneficial effect of curcumin on microbial metabolism stability and 
homeostasis in the gut. 
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2.  Transporters 
The predicted pathways based on the microbial composition profiles showed that 
bacterial transporters are predicted to decrease in the Il10
-/-
 mice, as opposed to the healthy WT 
mice on control diet (Table 2.5).  The addition of the curcumin-supplemented diet did not alter 
this prediction (Table 2.9).  However, the finding that “other ion-coupled transporters” are 
predicted to be higher in Il10
-/-
 mice compared to WT mice (Table 2.9) indicates that not all 
bacterial transporters will be reduced in the context of chronic inflammation.   
It would be advantageous to know which bacterial transporters are potentially decreased, 
as this may be an indicator about what could be taken up in to the bacterial cell as an energy 
source, especially if transporters change over the course of the disease progression or during the 
switch from inflammation to cancer.   
 
3.  Two-component systems 
PICRUSt analysis indicated that bacterial two-component systems are decreased in Il10
-/-
 
mice given the 0.5% curcumin-supplemented diet compared to Il10
-/-
 mice on the control (0% 
curcumin) diet (Table 2.9).  It was not identified as statistically different between tumor types or 
presence/absence of tumors.  Yet, this is intriguing, as the Il10
-/-
 mice given 0.5% curcumin had 
a striking reduction in tumor development for both spontaneous and AOM-induced tumors with 
no Il10
-/-
 mice on the 0.5% curcumin diet developing tumors (Figure 2.5).  The two-component 
system is associated with the bacteria’s ability to sporulate, gain antibiotic resistance, become 
competent (take in DNA) and to transition to a static phase (Mitrophanov et al., 2008).  
Sporulation was not predicted by PICRUSt to be different between the Il10
-/-
 mice and the WT 
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mice, or between the Il10
-/-
 mice on the control vs. on the 0.5% curcumin diet.  PICRUSt does 
not predict competence or antibiotic resistance.  However, Il10
-/-
 mice fed the 0.5% curcumin 
diet were predicted to have reduced cell motility (Table 2.9).  Curcumin has been observed to 
inhibit bacterial motility and cytotoxicity of Vibrio vulnificus (Na et al., 2011), to arrest 
Helicobacter pylori growth during infections (De et al., 2009), as well as inhibit biofilm 
formation in Pseudomonas aeruginosa (Rudrappa et al., 2008).  This suggests that the protective 
effect of 0.5% curcumin diet shifts the microbial composition to be more stationary, which may 
contribute to a decrease in microbial invasiveness and a decrease in overall disease severity.   
 
2. Future directions of curcumin as an anti-cancer agent 
There are many future directions in which to explore.  Increasing the bioavailability of 
curcumin may make the therapeutic outcome of this treatment even more effective.  Curcumin is 
considered poorly absorbed, quickly metabolized and quickly eliminated with low aqueous 
solubility (Ji et al., 2014).  A study from our lab using mice housed in specific pathogen free 
(SPF) conditions detected through HPLC analysis significant amounts (ranging from 1.54 ± 0.2 
mM to 7.54 ± 0.3 mM) of unmetabolized curcumin in the colon lumen for mice fed curcumin in 
their diets with doses ranging from 0.1% to 1% (Larmonier et al., 2008).    Nevertheless, it 
remains highly effective and much effort has been placed into increasing its bioavailability to the 
intestinal epithelium.  Increasing the bioavailability through the use of nanoparticles (Chuah et 
al., 2014 and Li et al., 2014), using plant exosomes as a delivery method (clinicaltrials.gov 
ID:NCT01294072)) and administering concomitantly with compounds, such as piperine (Shoba 
et al., 1998), are current strategies used to increase bioavailability of curcumin that we could 
explore in the laboratory or through collaboration.   
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Another avenue of research was suggested by Dr. Dirk Haller, who described his findings 
(unpublished) that using standard mouse chow for dietary supplements causes variation in 
microbial composition.  He recommends trying synthetic component based diet, as his research 
team has found this to cause less variability in the microbial composition, which made it easier to 
understand how their dietary supplementation was truly affecting the microbiota. 
A question arises as to how our research can contribute directly to human healthcare.  I 
propose consideration of the following clinical trials.   
 
 Clinical trial for use of curcumin in patients with IL10 polymorphisms 
Curcumin is tolerated well in healthy patients, but it is concerning that it may become toxic 
in the context of chronic inflammation.  There are many clinical trials that explore the tolerability 
of curcumin in healthy humans, but this needs to be explored with IBD patients, especially if it 
can be an effective prevention of the progression to colon cancer in high-risk patients with a long 
history of IBD, particularly Ulcerative Colitis.   I propose not only to test this in IBD patients, 
but to have two groups of patients recruited, one that tests positive for IL10 polymorphism and 
one that does not.  This will allow for a refinement of selecting patients that will most benefit 
from curcumin treatment. 
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 Clinical trial for use of curcumin in patients with colon cancer in the ascending vs. 
descending colon 
There are differences in the genetic mechanisms of colon cancer spatially between ascending 
and descending colon locations.  Furthermore, the microbial burden varies spatially within the 
colon, with the greater abundance being located in the distal regions of the colon.  If the bacteria 
are playing a large role in the initiation of cancer in the colon, this is also a promising 
therapeutic target that warrants more investigation.  The Il10
-/-
 mouse model system allows for a 
unique model system where mice spontaneously develop tumors in the proximal region, which 
corresponds to the ascending colon.  The Il10
-/-
 mice can be given AOM to promote tumors 
primarily in the distal region, which corresponds to the descending colon.  Even if curcumin did 
not reduce spontaneous tumors, it may reduce the severity, as demonstrated by the localization 
of beta catenin in the membrane of tumor tissue from mice given 0.5% curcumin, as it would be 
in healthy animals.  Conversely, the mice that were not given curcumin had aberrant beta 
catenin localization.  If curcumin can function by keeping tumors from progressing to 
malignancy or limiting the malignant potential of tumors, this would be very beneficial 
treatment.  I propose a clinical trial were patients would be selected for having either ascending 
or descending tumors and given curcumin.  This would also allow for refinement of selecting 
patients that will most benefit from curcumin treatment. 
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C. Summary and Conclusion 
Inflammatory bowel diseases are a major risk factor for colon cancer and intestinal 
microbiota have been identified as a trigger of inflammatory responses that affects the 
progression of colitis-associated colorectal cancer (CAC).  With diet being a key determinant of 
the gut microbial ecology, dietary interventions, such as curcumin, are an attractive avenue for 
the prevention of CAC. I hypothesized that curcumin would modulate the bacteria of AOM-
treated chronically-inflamed Il10
-/-
 mice to become similar in composition to that of healthy, 
untreated wildtype mice, thus restoring the colon homeostasis of the mice.   
Curcumin is effective in reducing the carcinogenicity of the chemical carcinogen 
azoxymethane (AOM) in a dose-dependent manner (Figure 2.5).  We explored whether or not it 
can modulate the microbiota on a global scale within the colon tissue and if that could be a 
potential mechanism of action.  We did not see a dramatic shift in microbial composition based 
solely on this treatment, although there were moderate differences in composition profiles at the 
most effective dose (0.5% curcumin in Il10
-/-
 mice treated with and without AOM compared to 
healthy untreated WT and the Il10
-/-
 mice on the 0% curcumin control diet)(Figure 2.9).   
Curcumin’s role as an anti-cancer agent is independent of its anti-inflammatory role.  We 
do not see a statistically significant reduction in the pro-inflammatory cytokine gene expression 
compared to the mice on the 0% curcumin control diet (Fig. 2.7).  Of all the doses, the 0.1% 
curcumin diet is the most effective at reducing inflammation, as shown in AOM-treated wildtype 
mice (for TNF- -treated Il10
-/-
 mice 
(IL-1ß, distal region) and PBS-treated wildtype mice (IL-17, proximal region).  This corresponds 
with published studies from our lab, where we previously showed that colon morphology was 
improved and pro-inflammatory cytokine production inhibited only at the 0.1% curcumin dose 
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when testing a range from 0.1% to 1%.  For that study, curcumin was used as a preventative 
agent in germ-free Il10
-/-
 mice and germ-free Il10
-/-
 mice given microbiota from mice housed in a 
non germ-free, specific-pathogen free facility (Larmonier et al., 2008).  This indicates, that 
curcumin’s role to reduce tumorigenesis is independent of its role to reduce inflammation and 
that both roles are, respectively, dose-dependent. 
Results from this study suggest that curcumin may reduce the severity and score of the 
tumors that form (Figure 2.6).  Furthermore, we did observe a striking difference in the 
microbial composition based on the tumor type of the sources of the samples, whether 
spontaneous or AOM-induced (Figure 2.10). 
This is a promising study that opens many avenues for future research to advance the 
fields of both microbial analysis in the gut environment and in colon cancer research.   
Curcumin was observed to have a beneficial effect as a modulator of microbial 
composition and as an anti-cancer agent in WT vs. Il10
-/-
 mice, as well as in mice with 
spontaneous vs. AOM-induced tumors.  Microbial composition profiles of Il10
-/-
 mice treated 
with curcumin corresponded with specific microbes associated with tumor-free colon tissue, 
namely Bifidobacterium and Lactobacillus.  Genotype is a strong driving factor behind 
statistically significant shifts in bacteria.  Tumor-free wildtype animals have greater microbial 
diversity than chronically inflamed Il10
-/-
 mice.  Functionally, untreated Il10
-/-
 mice have a shift 
in their microbial composition profile towards carbohydrate metabolism and a decrease in purine 
and pyrimidine metabolism, compared to WT, as well as a decrease in general bacterial 
transporters.  Curcumin treatment results in purine and pyrimidine metabolism being 
indistinguishable from that of WT mice, rather than lower.  Curcumin also is associated with 
predicted decreases in bacterial motility and the two-component system. 
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Figure 3.1: Summary of major findings of curcumin treatment.  Information derived from Tables 8 and 10 in Chapter 2.  
Diagram shows changes associated with going from a chronically-inflamed phenotype to a healthier, tumor-free phenotype: 
Increased abundance of bacterial taxa (Bifidobacterium, S24-7, Peptostreptococcaceae, Erysipeltrichaceae), increased pathways 
(purine and pyrimidine metabolism, DNA repair), decreased abundance of bacterial taxa (Bacteroidales), decreased pathways 
(membrane transport, two-component system, cell motility). 
 
As colon cancer has been the third most highly ranked cancer worldwide for incidence 
and mortality for many decades, there is a need for more effective therapeutics and 
understanding of this disease process.  Curcumin provides a non-invasive, naturally-derived, 
orally administered compound that has minimal side effects.  Curcumin is a promising 
therapeutic that could effectively reduce the tumor onset and burden associated with colon 
cancer. 
98 
 
ADDENDUM 
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Radhakrishnan VM, Ramalingam R, Larmonier CB, Thurston RD, Laubitz D, Midura-Kiela MT, 
McFadden R-M T., Kuro-O M, Kiela PR, Ghishan FK.  Post-Translational Loss of Renal 
TRVP5 Calcium Channel Expression, Ca(2+) Wasting and Bone Loss in Experimental Colitis.  
Gastroenterology.  2013.  In press. 
 
Larmonier CB, Laubitz D, Hill FM, Shehab KW, Lipinski L, Midura-Kiela MT, McFadden R-
M T., Ramalingam R, Hassan KA, Golebiewski M, Besselsen DG, Ghishan FK, Kiela PR.  
Reduced Colonic Microbial Diversity is Associated with Colitis in NHE3-deficient mice.  
American Journal of Physiology, Gastrointestinal and Liver Physiology.  2013.  Epub ahead of 
print. 
 
Larmonier CB, McFadden R-M T., Hill FM, Schreiner R, Ramalingam R, Besselsen DG, 
Ghishan FK, Kiela PR.  High Vitamin D diet Administered During Active Colitis Negatively 
Affects Bone Metabolism in Adoptive T-cell Transfer Model.  American Journal of Physiology, 
Gastrointestinal and Liver Physiology. 2013. 305(1):G35-46. 
 
Navath S, Rao V, Woodford R-M T., Midura-Kiela M, Ahad A, Alleti R, Kiela P, Mash E.  
Design, Synthesis and Testing of a Molecular Truck for Colonic Delivery of 5-Aminosalicylic 
Acid.  ACS Medicinal Chemistry Letters.  2012.  3:710-14. 
 
Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, Woodford R-M T., Davis 
BK, Uronis JM, Herfarth HH, Jobin C, Rogers AB, Ting JP.  NLRP12 suppresses colon 
inflammation and tumorigenesis through the negative regulation of noncanonical NF-kB 
signaling.  Immunity.  2012.  36(5):742-54. 
 
Allen IC, TeKippe EM, Woodford R-M T., Uronis JM, Holl EK, Rogers AB, Herfarth HH, 
Jobin C, Ting JP.  The NLRP3 inflammasome functions as a negative regulator of tumorigenesis 
during colitis-associated cancer. Journal of Experimental Medicine. 2010.   207(5):1045-56. 
 
Van Deventer HW*, Burgents JE*, Wu QP, Woodford R-M T., Brickey WJ, Allen IC, 
McElvania-Tekippe E, Serody JS, Ting JP.  The inflammasome component NLRP3 impairs 
antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived 
suppressor cells. Cancer Research. 2010. 15;70(24):10161-9. 
*co-first authors 
 
 
Presentations 
 
2014  The Role of Curcumin in Modulating Colonic Microbiota During 
  Inflammation and Carcinogenesis 
 Digestive Disease Week International Conference, lecture 
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 Emory University STEM Research and Career Symposium, poster 
 
2013  Design, Synthesis and Testing of a Molecular Truck for Colonic Delivery  
  of 5-Aminosalicylic Acid: Translational Medicine Symposium at the  
  University of North Carolina in Chapel Hill, poster presentation 
 
  Antagonism of TGF-β pathway in dendritic cells by TLR stimulation is 
  TRIF dependent, poster presentations:  
 University of Arizona in Tucson, Frontiers in Immunobiology & 
Immunopathogenesis Symposium  
 Digestive Disease Week (international conference: Orlando, FL) 
 
2011  Inflammasome Deficiency Increases Anti-Cancer Vaccine Efficacy: 
 UNC Dental Research and Review Day oral presentation 
 UNC Translational Medicine Symposium poster presentation 
 
2010  Role of NLRX1 in colitis-associated colon cancer: UNC 
  Center for Gastrointestinal Biology and Disease research competition,  
  oral presentation 
 
2009  T cell Expression of Coronin 1A has a role in induction of Graft-versus- 
  host disease. UNC Dental Research and Review Day poster presentation. 
   
 
Training Opportunities 
2010-  Howard Hughes Medical Institute Med to Grad training initiative 
  certificate program in Translational Medicine 
 
 
Accolades 
2013  2
nd
 place for poster presentation “Design, Synthesis and Testing of a  
  Molecular Truck for Colonic Delivery of 5-Aminosalicylic Acid.”  
  Translational Medicine Symposium at University of North Carolina in  
  Chapel Hill, co-sponsored by Howard Hughes Medical Institute Program  
  in Translational Medicine and the Cancer Cell Biology Training Program 
 
2011  Turner Award: American Association for Dental Research 
  for UNC DRRD 2011 oral presentation “Inflammasome Deficiency 
  Increases Anti-Cancer Vaccine Efficacy.” 
 
 
Teaching/Mentorship/Outreach 
 
2013 
 Graduate Research Mentor for Summer Institute for Medical Ignorance (SIMI) program 
to advance education beyond the classroom, primarily for students from disadvantaged 
environments – train and prepare two high school students to complete independent 
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projects with an emphasis on understanding the techniques and assays used for the 
research.  Students prepared oral presentations on techniques learned and experimental 
findings.  This year, the students assisted with extraction of bacterial DNA, running PCRs 
and understanding the microbial contribution to inflammation during the course of 
disease from stool samples of research mice undergoing treatment for colon cancer. 
 Volunteer for BIOTECH genetics outreach program at University of Arizona, Tucson 
Book Festival with the Bio5 Institute.  Volunteers help children understand and work 
through various educational activities about DNA structure, such as extraction and 
interpreting electrophoresis gels (mini “crime” scene investigation, paternity testing, 
construct candy DNA structure, etc.). 
2012   
 Graduate Research Mentor for Keep Engaging Youth in Science (KEYS) Program for 
highly achieving Arizona high school interns.  Research mentor for 5 weeks – train and 
prepare student to become independent with their own experiments and to display their 
findings at the KEYS Student Research Showcase.  This year, the student (Bob and 
Nancy Clark sponsored intern) helped with my graduate research project and presented, 
“The Role of Curcumin in Modulating Colonic Microbiota During Inflammation and 
Carcinogenesis.”  
 Preceptor:  teach a laboratory section with a fellow graduate student TA (Adiv Johnson) 
of an undergraduate level Anatomy and Physiology class PSIO 202 Spring semester 
(2012) at the University of Arizona in Tucson.  The Course Director is Dr. Eric Price.   
2011 
 Judge for North Carolina Student Academy of Science’s statewide science competition for 
Middle and High School students: review submitted research papers for assigned section 
and give verbal and written comments teaching them how to improve their scientific 
writing and oral presentation skills.  Rank and select students for awards.  
 Student guest lecturer “Scientist Ambassador” for North Carolina DNA Day.  Volunteer 
for one day in April 2011 to teach a high school class with a fellow graduate student 
promoting Biological Sciences.  Powerpoint and science demonstration materials are 
provided and commemorate the Human Genome Project. 
 Teaching Assistant:  teach a laboratory section of an undergraduate level Anatomy and 
Physiology class BIOL252 Summer Session I (2011) at the University of North Carolina 
in Chapel Hill.  The Course Director is Dr. James Fiordalisi. 
 Preceptor:  teach a laboratory section with a fellow graduate student TA (Kate Smith) of 
an undergraduate level Anatomy and Physiology class PSIO201 Fall semester (2011) at 
the University of Arizona in Tucson.  The Course Director is Dr. Eric Price.   
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